Study Database

Mechanistically, NNMT overexpression in tubular epithelial cells exacerbates senescence and partial epithelial-to-mesenchymal transition, while selective NNMT inhibition in senescent kidney cells, organoids, and in vivo is protective. Altogether, these findings position NNMT as a promising therapeutic target to reduce tubular senescence and fibrosis in early CKD.

Limitations: No placebo control reported.

Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

Limitations: No placebo control reported. Review article — no new primary data.

BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.

Limitations: No placebo control reported. Review article — no new primary data.

Injection of FOXO4-DRI in both naturally aged and induced aging mice effectively suppressed aortic aging and improved aortic function. Additionally, we found that FOXO4-DRI alleviates endothelial cell senescence induced by OGD, thereby enhancing endothelial cell function.

Limitations: Animal study only — human translation uncertain.

Mechanistically, LL-37-induced CXCL10 production relied on the Jak1/signal transducer and activator of transcription 1 signaling pathway. In summary, our findings provide a crucial link to keratinocyte-T-cell crosstalk, and blockade of the CXCL10:CXCR3 axis or Jak1/signal transducer and activator of transcription 1 pathways can be an effective anti-inflammatory strategy to reduce rosacea inflammation by restricting pathogenic T-cell infiltration.

Limitations: No placebo control reported.

Thus, NAD+ restoration coordinates RNA splicing fidelity with downstream proteostatic systems, establishing a metabolic - transcriptional checkpoint for neuronal quality control. This finding expands the paradigm of autophagy regulation, positioning metabolic splice-switching as a crucial mechanism to maintain proteostasis and suggesting new strategies to combat aging-related neurodegenerative diseases.

Limitations: No placebo control reported.

At 1 month, the NAD+ group demonstrated a significantly greater improvement in LVEF compared to the placebo group (45.44 ± 8.55% vs. 42.44 ± 9.09%, p = 0.024).

Limitations: Standard limitations apply. Check original paper for full discussion.

Elamipretide is also under phase III clinical development for use in the treatment of dry age-related macular degeneration and mitochondrial myopathies. This article summarizes the milestones in the development of elamipretide leading to this first approval for Barth syndrome.

Limitations: No placebo control reported. Review article — no new primary data.

Elamipretide Hydrochloride. (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026)

Limitations: Animal study only — human translation uncertain.

Finally, translational opportunities are appraised with attention to pharmacokinetics, peptide stability and delivery strategies. Key challenges moving forward include validating efficacy in additional clinically relevant models, overcoming peptide instability and completing comprehensive safety assessments.

Limitations: No placebo control reported. Review article — no new primary data.

Using high-throughput screening, we develop a potent and specific NNMT inhibitor that reduces the tumour burden and metastasis in multiple mouse cancer models and restores immune checkpoint blockade efficacy by decreasing CAF-mediated recruitment of MDSCs and reinvigorating CD8+ T cell activation. Our findings establish NNMT as a central CAF regulator and a promising therapeutic target to mitigate immunosuppression in the tumour microenvironment.

Limitations: No placebo control reported.

This was accompanied by decreased pro-inflammatory and pro-fibrotic gene expression in plasma and LV tissue and reduced macrophage infiltration in LV and visceral adipose tissue, highlighting the anti-inflammatory and anti-fibrotic effects of NNMT inhibition. Targeting the NNMT is cardioprotective and holds promise for treating HFpEF patients with an unfavorable cardiometabolic phenotype.

Limitations: Animal study only — human translation uncertain.

This generated the attention of experts, as BPC 157 has been offered for sale on many websites. We also present recent interest in BPC 157 as reflected in a number of patent applications and granted patents.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.

Limitations: No placebo control reported. Review article — no new primary data.

BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

However, this has not slowed the recent exponential growth of the multi-billion-dollar industry in the development of therapeutic peptides. As orthopaedic surgeons and team physicians, we should stay up to date with the latest pharmacokinetic, safety, ethical, and legal profiles and regulations regarding synthetic peptide supplementation for injury recovery and sports performance optimization in our patients, from elite athletes to fitness fanatics, because they will continue to seek the latest and greatest in treatment options and will be approaching us with questions on their results, risks, and benefits.

Limitations: No placebo control reported. Review article — no new primary data.

The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels. The BPC-157 peptide infusion was tolerated, with no side effects reported.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.

decrease), always combined with the counteraction of free radical formation, and, in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and Alzheimer's disease-like disturbances. Thus, BPC 157 therapy means targeting angiogenesis and NO's cytotoxic and damaging actions but maintaining, promoting, or recovering their essential protective functions.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Immediately post-injury, and at 1, 2, 3, 5, 7, 14, 21, 28, 60, and 90 days post-injury, quadriceps muscle-to-bone detachment showed definitive healing failure (impaired walking and permanent knee flexure). Contrarily, macro/microscopic, ultrasonic, magnetic resonance, biomechanical, and functional assessments revealed that BPC 157 therapy recovering effects for all time points were consistent.

Limitations: Animal study only — human translation uncertain.

This serves to counteract multiorgan and vessel failure, including lesions and hemorrhages in the brain, heart, lung, liver, kidney and gastrointestinal tract, thrombosis, peripherally and centrally, intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension, occlusion/occlusion-like syndrome, advanced Virchow triad circumstances, and free radical formation acting as a membrane stabilizer and free radical scavenger. Likewise, not only in ACS/IAH resolving, but also in other occlusion/occlusion-like syndromes, this "bypassing key" could be an effect of the essential endothelial cytoprotective capacity of BPC 157 and a particular modulatory effect on the NO-system, and a rescuing impact on vasomotor tone.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

Limitations: Animal study only — human translation uncertain.

This article discusses the lengthy review by Pedrag Sikiric and twenty one (21) co-authors in Inflammopharmacology (2024) 32:3119-3161.

Limitations: No placebo control reported.

Moreover, despite the considerable volume of research on the biological and pharmacodynamic characteristics of Epitalon, the quantity of physico-chemical and structural investigations of this peptide remains quite limited. This review aims to conclude the most important findings from such studies, thus presenting the current state of knowledge on Epitalon.

Limitations: No placebo control reported. Review article — no new primary data.

Only a minor increase in ALT activity was observed in Normal cells, thereby showing that it was specific to cancer cells. Our data suggests that epitalon can extend telomere length in normal healthy mammalian cells through the upregulation of hTERT mRNA expression and telomerase enzyme activity.

Limitations: No placebo control reported.

More mechanistic investigations are needed to confirm Epitalon's benefits and safety. Developing ophthalmic forms of Epitalon may enhance its delivery directly to the retina, potentially improving its therapeutic efficacy.

Limitations: No placebo control reported.

Furthermore, we show that p53 phosphorylation enhances the affinity for both FOXO4 and FOXO4-DRI. Summarizing we provide a detailed characterization of the interaction of p53 with FOXO4 and FOXO4-DRI which is the basis for development of p53 inhibitors to treat diseases linked to cellular senescence such as cancers.

Limitations: No placebo control reported.

Our study indicates that upregulation of p53-pS15 and p16 maintains a persistent senescent microenvironment to promote cell cycle arrest and apoptosis resistance in keloid fibroblasts. FOXO4-DRI shows potential as a treatment targeting the senescence and apoptosis resistance, and holds promise as an approach to prevent the aggressiveness and relapse of keloids.

Limitations: No placebo control reported.

Based on cellular studies, undoubtedly, GHK can be considered as an anti-wrinkle ingredient. Although GHK-Cu and Pal-GHK have been of interest as effective peptides to be incorporated in the anti-wrinkle products, there is a surprising absence of clinical studies using them.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

These peptide derivatives behave as copper ionophores, utilizing Cu2+ present in the culture medium; also, an increase in the metal intracellular level occurs with a consequent stimulation of the copper-driven signaling pathways that produce the expression/release of trophic (Brain-Derived Neurotrophic Factor, BDNF, and Bone Morphogenetic Protein 2, BMP-2) and angiogenic (Vascular Endothelial Growth Factor, VEGF) proteins. Copper chaperons for SOD1, CCS, and Antioxidant 1 (Atox-1) are the copper chaperones that act as transcription factors.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

The results highlight copper's role in promoting the expression and release of certain trophic, angiogenic, and osteogenic factors, including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), as well as bone morphogenetic protein-2 (BMP-2). The protective and regenerative activities of the metal ion are related to the translocation of its intracellular chaperones Copper Chaperone for Superoxide Dismutase (CCS) and Antioxidant-1 (Atox1) to the nucleus where they act as transcription factors.

Limitations: No placebo control reported.

An analysis of the literature data reveals that the transport of liposomes containing GHK-Cu received little attention. This research gap gives an impetus to the methodological developments for assessing the effect of liposomes on GHK-Cu transportation and trafficking.

Limitations: No placebo control reported. Review article — no new primary data.

GHK-Cu alleviated weight loss, improved the disease activity index (DAI), reduced colonic edema and shortening, attenuated inflammatory damage, increased goblet cell numbers, suppressed inflammatory cytokines such as TNF-α, IL-6, and IL-1β, and promoted mucosal repair. Additionally, a co-culture system of MCECs and MPMs revealed that GHK-Cu facilitated MCECs healing, impaired by DSS, by upregulating ZO-1 and Occludin expression.

Limitations: Animal study only — human translation uncertain.

In this process, H&E staining and Masson staining revealed significant collagen deposition. These findings further confirm that GHK-Cu@CMHA is a novel injectable soft tissue filler with good anti-inflammatory and antioxidant properties, which holds well potential for inflammation inhibition.

Limitations: Animal study only — human translation uncertain.

We speculate that maintaining amino acid concentrations or raising insulin, glucose, and/or oxygen concentrations to values consistent with normally growing fetuses during IGF-1 LR3 treatment may be necessary to increase fetal growth in the setting of placental insufficiency and FGR.NEW & NOTEWORTHY IGF-1 LR3 treatment administered directly into growth-restricted fetal sheep circulation did not improve fetal growth or attenuate circulating insulin or fetal GSIS. Importantly, IGF-1 LR3 treatment reduced circulating amino acids, notably branched-chain amino acids, which have been shown to potentiate GSIS and protein accretion supporting fetal growth.

Limitations: Animal study only — human translation uncertain.

In male 5XFAD mice, IN LR3-IGF-1 treatment improved body composition, but did not significantly alter cognitive symptoms, as assessed by multiple assays. In cortex, LR3 treatment improved some facets of pathology, including a reduction in filamentous plaques, and increase in inert plaques, corresponding with a reduction in low molecular weight Aβ oligomers.

Limitations: No placebo control reported.

The IGF-1 LR3-controlled releasing decellularized conduit significantly improved axonal regeneration and showed comparable performance to autologous nerve grafts, without inducing systemic toxicity. This novel conduit demonstrates the potential of plant-based biomaterials for effective peripheral nerve repair.

Limitations: Animal study only — human translation uncertain.

Author Correction: Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. (Nature communications, 2025)

Limitations: Animal study only — human translation uncertain.

Silencing SIRT1 abolished the protective effects of Kp-10, highlighting the essential role of SIRT1 in its anti-senescence action. These findings suggest that Kp-10 may be a promising therapeutic strategy for OA by mitigating chondrocyte senescence and improving cellular function by modulating the SIRT1 and p53/p21 pathways.

Limitations: No placebo control reported.

We found that KP-10 levels were reduced in both CA patients and mouse models. In CA mice, Gpr54 expression in the Circle of Willis (COW) was also decreased.

Limitations: No placebo control reported.

These findings indicate that KP-10 plays a crucial role in suppressing EC progression and represents a promising therapeutic target for clinical treatment. However, more comprehensive studies are needed to fully elucidate the underlying mechanisms and explore the clinical potential of KP-10 in EC therapy.

Limitations: No placebo control reported.

These immunomodulatory actions occurring at concentrations lower than those microbicidal uncover a new guise for cathelicidin modulating the epithelial barrier against A/E pathogens. Recognizing native cathelicidin's functions in a specified disease setting (e.g., colitis) will help establish it as an anti-infectious immunomodulator.

Limitations: No placebo control reported.

Finally, the LL-37-induced EndMT was inhibited by Akt and nuclear factor-kappa B (NF-κB) inhibitors, suggesting that LL-37 induces EndMT by activating Akt and NF-κB. These observations speculate a role of LL-37 in the pathogenesis of atherosclerosis as an EndMT inducer.

Limitations: No placebo control reported.

Here we present the case of an otherwise healthy man in his early 30s, who developed transaminitis after consuming MK-677 for 2 months before presentation. Liver function tests eventually returned to normal limits after stopping the supplement.

Limitations: No placebo control reported. Case study — cannot establish causation.

Linearity was verified from 0.5 to 250 pg/mg (R2 = 0.9961). The limit of detection was 0.1 pg/mg.

Limitations: No placebo control reported.

Compound 4b exhibited superior pharmacokinetic exposure in dogs (oral bioavailability: 43.6%; half-life: 1.2 h) relative to other species. This study details the optimization of 4b, which demonstrates a promising pharmacological profile for clinical translation as a growth hormone replacement therapy.

Limitations: No placebo control reported.

Eighteen different molecules, within the scope of the study, were reported with as top 5: ibutamoren, ligandrol, ostarine, cardarine and andarine. From the limited quantitative data reported, it can be assumed that the majority of the samples contain active doses and some are even overdosed, so health risks for the consumers cannot be neglected.

Limitations: No placebo control reported.

Our findings establish MOTS-c as a dual-function molecule-acting via ROS-CK2A-MYH9 signaling to activate nuclear antioxidant defenses and serving as a prognostic biomarker for CPB-related complications. This study bridges mitochondrial dynamics, nuclear transcriptional regulation, and clinical outcomes, offering novel preventive avenues for IRI-associated pathologies.

Limitations: No placebo control reported.

In addition, the key role of MOTS-c in the major diabetes-related complications is specifically explored, with a special focus on its protective and therapeutic potential in diabetic cardiomyopathy. Beyond summarising its multifaceted roles, this review also uniquely compiles and discusses the distinct exogenous MOTS-c therapeutic approaches, including varying doses and dosing schedules, applied in preclinical metabolic disease studies, thereby providing valuable insights into future translational research.

Limitations: No placebo control reported. Review article — no new primary data.

A Mighty Mitochondrial Microprotein: The Protective Role of MOTS-c in Acute Lung Injury. (American journal of respiratory cell and molecular biology, 2025)

Limitations: Animal study only — human translation uncertain.

In addition, the inhibition of NAD+-degrading enzymes (e.g., poly ADP-ribose polymerase (PARP), cluster of differentiation 38 (CD38), and selective androgen receptor modulators (SARMs)) increases the tissue intracellular NAD+ content, and supplementation with NAD+ precursors (e.g., β-nicotinamide mononucleotide (NMN), nicotinamide riboside, etc.) also significantly elevates myocardial NAD+ levels to ameliorate heart failure. This study provides a theoretical basis for understanding the central role of NAD+ in mitochondrial homeostasis and for the development of targeted therapies for heart failure.

Limitations: No placebo control reported. Review article — no new primary data.

In the probe test of the Morris water maze, the cuprizone group spent a significantly smaller proportion of time in the target quadrant than the control group did (16.32% vs. 31.66%, p = 0.006).

Limitations: Animal study only — human translation uncertain.

We revealed a depression in open-field activity and Y-maze performance with NADH supplementation, an indicator of cognitive recovery in rodents. The broad implications of NAD+ in aging are likely to shape supplementation trends, highlighting the importance of understanding the potential influence of administering NAD+ on anesthetic sensitivity and recovery.

Limitations: Animal study only — human translation uncertain.

In this study, we investigate the effect of acute supplementation of nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide, in a lipopolysaccharide-induced delirium mouse model. While Nicotinamide adenine dinucleotide did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice, a comprehensive cytokine profile analysis did reveal rescue of plasma IFNγ levels by nicotinamide mononucleotide supplementation and partial improvement on the levels of IL-12p40, RANTES, LIX, and IL-17 which were sex-dependent.

Limitations: Animal study only — human translation uncertain.

Instead, there was a depression in open-field activity and no change in Y-maze performance with NADH supplementation, indicators of locomotive and cognitive recovery in rodents. The broad implications of NAD+ in aging are likely to shape supplementation trends, highlighting the importance of understanding the potential influence of administering NAD+ on anesthetic sensitivity and recovery.

Limitations: Animal study only — human translation uncertain.

This pilot study provides critical evidence by examining peripheral endothelial function, cerebrovascular responses, and cognitive performance. Its multifaceted approach lays the groundwork for future trials to refine effect sizes and validate NR's potential to counter vascular aging and cognitive decline in PAD.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.

LF-NAD+, enhances the anti-aging effects of NAD+ on vascular and skin cells. Such in vitro findings might indicate a potential anti-aging role in the microcirculation and in the epidermidis.

Limitations: Animal study only — human translation uncertain.

In a "Two-hit" HFpEF mouse model, we observed increased AF susceptibility with prolonged modeling. Additionally, bioinformatics analysis and in vivo and in vitro studies highlighted progressive ZBP1-mediated PANoptosis accompanied by mitochondrial dysfunction in HFpEF atria.

Limitations: In-vitro study — may not reflect in-vivo effects.

Despite the large number of available studies, a high clinical, statistical, and methodological heterogeneity was observed. More methodologically rigorous studies are needed to clarify the effectiveness of each protocol and modality of intervention.

Limitations: No placebo control reported. Review article — no new primary data.

From 89 studies (mean follow-up: 5.2 years), conversion risk was 41.5% (38.3%-44.7%) in clinical and 27.0% (22.0%-32.0%) in population-based studies, with Alzheimer's dementia as the most common outcome. Stability rates were 49.3% (clinical) and 49.8% (population).

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Finally, our findings revealed that mice lacking TREK-1 gained more fat mass and had worse glucose tolerance when fed a high-fat diet (HFD) compared to the wild-type controls. The findings demonstrate that increase of the membrane potential at adipocytes through the downregulation of TREK-1 can influence the progression of adipogenesis.

Limitations: Animal study only — human translation uncertain.

We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations). Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.

Limitations: No placebo control reported. Review article — no new primary data.

Clinicians must discern important distinctions between flibanserin, bremelanotide, and other agents when managing premenopausal HSDD. Further research with the most suitable clinical endpoints and consideration of patient factors are crucial before widespread adoption of flibanserin and bremelanotide.

Limitations: No placebo control reported. Review article — no new primary data.

Moreover, possible applications in protection from infections and anti-aging properties are discussed. Semaglutide enhancement of the core molecular mechanisms involved in the progress of obesity and diabetes, although mostly preclinical, may provide a framework for future research applications in human diseases overall.

Limitations: No placebo control reported. Review article — no new primary data.

Further studies can assess if there is a need to modify pre-operative guidelines to account for patient using semaglutide and how delayed gastric emptying and constitpation will affect surgical outcomes and complications. While semaglutide therapy for diabetes mellitus has been established, there is a need for extensive research on repurposing semaglutide in neurodegenerative disease treatment.

Limitations: No placebo control reported.

Its safety profile is generally favorable, though gastrointestinal side effects can occur.By addressing multiple interconnected conditions, semaglutide is poised to transform care for patients at high risk of heart, kidney, and metabolic complications. Further research is exploring new dosing methods, combinations with other medications, and expanded use in non-diabetic populations to maximize its benefits.

Limitations: No placebo control reported. Review article — no new primary data.

The association of NAION with small, crowded discs, optic disc oedema and peripapillary exudation suggests that semaglutide-related NAION may result from changes in perfusion that lead to venous dilation and, presumably, to venous congestion during relative hypoglycaemia. Given the retrospective nature of the epidemiological studies, causality cannot be inferred, but a cautious approach to the use of semaglutide and other powerful glycaemia-reducing agents seems warranted, particularly in patients with crowded optic discs, a characteristic that can be identified by proactive eye examination for disc-at-risk characteristics by the use of optical coherence tomography.

Limitations: Review article — no new primary data.

Semax improved SCI functional recovery and inhibited LMP-related pyroptosis in SCI mice and neuroinflammation models, by decreasing oxidative stress. RNA-seq and other analyses found that Semax regulated the ubiquitin specific protease USP18.

Limitations: Animal study only — human translation uncertain.

3774 DEGs (fold change > 1.5 and Padj < 0.05) were identified under ischemia conditions, whereas 1539 and 2066 DEGs were revealed under Semax and ACTH(6-9)PGP peptides at 24 h after tMCAO. Furthermore, both peptides significantly reduced expression distortions caused by ischemia for 1171 genes associated with immune and neurosignaling pathways.

Limitations: Animal study only — human translation uncertain.

Finally, both MIA-602 and MIA-690 enhanced radiosensitivity in primary human NSCLC cells. These findings highlight the potential of GHRH antagonists as radiosensitizers in NSCLC treatment.

Limitations: No placebo control reported.

Further research may expand its application to other diseases involving mitochondrial dysfunction as well as investigate long-term efficacy and safety of the drug. The following review synthesizes current knowledge of the structure, mechanisms of action, and the promising therapeutic role of Elamipretide in stabilizing mitochondrial fitness, improving mitochondrial bioenergetics, and minimizing oxidative stress.

Limitations: No placebo control reported. Review article — no new primary data.

SS-31@Fer-1 significantly improved H/R-induced cardiomyocyte viability and reduced LDH and CK-MB levels. Compared to the Fer-1 group, SS-31@Fer-1 reduced GSH and increased MDA levels, enhancing mitochondrial integrity and function.

Limitations: Animal study only — human translation uncertain.

Additionally, dietary interventions and novel regulators such as adenogens are emerging as promising strategies to modulate mitochondrial function and attenuate kidney disease progression. Future research should address the gaps in understanding the role of mitophagy in CAKUT and optimize targeted delivery systems for precision therapies.

Limitations: No placebo control reported. Review article — no new primary data.

Elamipretide continues to show promise as a potential therapy for mitochondrial disorders. New basic science advances have improved understanding of elamipretide's MOA, enabling a better understanding of the molecular consequences of elamipretide-cardiolipin interactions.

Limitations: No placebo control reported. Review article — no new primary data.

Challenges include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence. Advances in smart delivery systems, drug formulations, and predictive models, alongside interdisciplinary collaboration, will be crucial in achieving personalized, effective, and sustainable retinal therapies.

Limitations: No placebo control reported. Review article — no new primary data.

We further demonstrate that telomere elongation during ICM formation is controlled by mitochondrial-nuclear communication at fertilization. Using mitochondrially-targeted therapeutics (BGP-15, MitoQ, SS-31, metformin) we demonstrate that it is possible to modulate the preimplantation telomere resetting process and restore deficiencies in neonatal telomere length.

Limitations: Animal study only — human translation uncertain.

Affected males transmit the TAFAZZIN pathogenic variant to all of their daughters and none of their sons. If the TAFAZZIN pathogenic variant has been identified in an affected family member, identification of female heterozygotes and prenatal/preimplantation genetic testing for Barth syndrome are possible.

Limitations: No placebo control reported. Review article — no new primary data.

In summary, glutamine effectively ameliorated inflammation and the occurrence of apoptosis by downregulating the pro-inflammatory and pro-fibrotic corneal epithelial cells subclusters and the related I&#x3ba;B&#x3b1;/NF-&#x3ba;B signaling. The present study suggests that glutamine metabolism plays a critical, previously unrecognized role in DED and proposes an attractive strategy to enhance glutamine metabolism by inhibiting the enzyme GLS1 and thus alleviating inflammation-driven DED progression.

Limitations: No placebo control reported.

The beneficial effects of T&#x3b2;4 were also revealed in 5xfAD model mice. Thus, this study has identified T&#x3b2;4 as a neuroprotective factor that may mitigate altered neurogenesis and AD pathology, highlighting a potential for disease intervention.

Limitations: No placebo control reported.

pDC depletion during house mite dust challenge enhanced CCR2-dependent inflammatory monocyte-derived cell accumulation, leading to exacerbated TH2-mediated allergic asthma phenotypes. RNA-sequencing analysis revealed that the anti-inflammatory peptide thymosin &#x3b2;4 (T&#x3b2;4) was among the most upregulated genes in asthmatic lung pDCs.

Limitations: No placebo control reported.

Plasma CCN5 levels were significantly reduced and correlated closely with the degree of restenosis in ISR patients. CCN5 expression was significantly decreased in VSMCs of stent-implanted porcine coronary segments and injured mouse femoral arteries, especially in synthetic VSMCs.

Limitations: No placebo control reported.

This process mitigates oxidative stress, reduces apoptosis, and promotes revascularization, thereby improving the quality and volume retention of fat grafts. Our findings provide a novel mechanistic insight into the enhancement of fat graft survival and suggest that mitochondrial transplantation and T&#x3b2;4 are potential therapeutic strategies to improve clinical outcomes in autologous fat transfer procedures.

Limitations: No placebo control reported.

Furthermore, MN@EVsT&#x3b2;4 patches showed significant efficacy in reversing senescence and promoting wound healing in diabetic wound models. Thus, the engineered ADSC-EVs, combined with separable microneedle patches, represent a promising bioengineering strategy for clinical wound management.

Limitations: No placebo control reported.

Seventy-three participants were randomized 3:2 to tesamorelin or SOC (2&#x2005;mg subcutaneously daily). The primary outcome was the change in neurocognitive performance at 6 months, with secondary outcomes including WC, mood, and daily functioning.

Limitations: Standard limitations apply. Check original paper for full discussion.

It represents a promising therapeutic approach to counteract age-related immune dysfunction and inflammation, potentially by slowing the aging process. Further research is needed to validate its long-term efficacy and safety in geriatrics.

Limitations: No placebo control reported. Review article — no new primary data.

Among 41&#x202f;222 adults meeting the study criteria (semaglutide, 32&#x202f;029; tirzepatide, 9193), 18&#x202f;386 remained after propensity score matching. The mean (SD) age was 52.0 (12.9) years, 12&#x202f;970 were female (70.5%), 14&#x202f;182 were white (77.1%), 2171 Black (11.8%), 354 Asian (1.9%), 1679 were of other or unknown race, and 9563 (52.0%) had T2D.

Limitations: No placebo control reported.

The 160 participants (pooled tirzepatide doses n&#x2009;=&#x2009;124, placebo n&#x2009;=&#x2009;36) with baseline and end of study DXA data were 73% female and had a mean weight of 102.5&#x2009;kg and body mass index of 38.0&#x2009;kg/m2. The change in body weight, fat mass and lean mass from baseline to Week 72 was -21.3%, -33.9% and -10.9% with tirzepatide and -5.3%, -8.2% and -2.6% with placebo, respectively (p&#x2009;<&#x2009;0.001 for all comparisons).

Limitations: Standard limitations apply. Check original paper for full discussion.

A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).

Limitations: No placebo control reported.

In the clinical trial, tirzepatide appeared to have no impact on metabolic adaptation but led to increased fat oxidation and reductions in appetite and calorie intake during an ad libitum test meal (vs. This is the first study to provide insights into the mechanisms of action of tirzepatide on weight loss with respect to calorie intake, energy expenditure, and macronutrient utilization.

Limitations: Standard limitations apply. Check original paper for full discussion.

Between May 10, 2021, and June 24, 2023, 413 participants were screened, and 267 were randomly assigned. Due to exclusion of one study site, the mITT population was 225 participants (133 [59%] men and 92 [41%] women, mean age 50&#xb7;8 [SD 10&#xb7;7] years), with 73 in the tirzepatide 10 mg group, 77 in the tirzepatide 15 mg group, and 75 in the placebo group, of whom 192 (85%) completed both study and treatment.

Limitations: Standard limitations apply. Check original paper for full discussion.

Benchmarking of the 2 trial emulations demonstrated high agreement on all prespecified metrics. In analyses using expanded eligibility criteria, 58&#x202f;333 patients were included in the semaglutide vs sitagliptin cohort, 11&#x202f;257 for tirzepatide vs sitagliptin, and 28&#x202f;100 for tirzepatide vs semaglutide.

Limitations: Standard limitations apply. Check original paper for full discussion.

Whether cardiovascular benefits will be found with dual GLP-1/GIP receptor agonists remains uncertain, and the contribution of GIP receptor activation to cardiovascular risk has not been established. Several ongoing large-scale cardiovascular outcome trials for tirzepatide will provide a clearer understanding of where tirzepatide should be positioned in the treatment of established atherosclerotic cardiovascular disease or in people at high risk, in relation to current standard-of-care cardioprotective agents and approaches.

Limitations: Review article — no new primary data.

A total of 282 adults were randomly assigned to tirzepatide (n&#x2009;= 139) or dulaglutide (n&#x2009;= 143). Change from baseline in HbA1c at week 40 was -1.44% (SE, 0.07) with tirzepatide, 15 mg or MTD, and -0.67% (SE, 0.08) with dulaglutide, 4.5 mg or MTD (estimated treatment difference, -0.77% [95% CI, -0.98% to -0.56%; P&#x2009;<&#x2009;0.001]).

Limitations: No placebo control reported.

5A1MQ treatment dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia in DIO mice. Liver histology from 5A1MQ-treated DIO mice showed attenuated hepatic steatosis and macrophage infiltration, and correspondingly reduced liver weight, size, and triglyceride levels.

Limitations: Animal study only — human translation uncertain.

Furthermore, close BPC 157/NO-system relations with the gasotransmitters crossing the cell membrane and acting directly on molecules inside the cell may envisage particular interactions with receptors on the plasma membrane of their target cells. Finally, there is nerve-muscle relation in various muscle disturbance counteractions, and nerve-nerve relation in various encephalopathies counteraction, which is also exemplified specifically by the BPC 157 therapy application.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Moreover, the healing of fistulas, both external and internal, colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, colovesical, and rectovaginal in rats, perceived as anastomoses made between two different tissues which are normally not connected, may also be indicative. This may be a particular reconnection of the parts of the gastrointestinal tract to re-establish adequate integrity depending on the tissue involved, given that both various intestinal anastomoses and various fistulas (intestinal and skin were accordingly healed simultaneously as the fistulas disappeared) were all healed.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Complete resolution of symptoms after one treatment was reported in 10 of 12 patients, who rated their success at 100%. The remaining 2 of 12 patients rated their success at 80%, with most symptoms resolved but about 20% of their symptoms lingering.

Limitations: No placebo control reported.

Contrary, all BPC 157-treated rats have closed both defects, duodenal and colonic, no fistula leakage (finally, maximal instilled volume corresponds to healthy rats), no cachexia, the same weight as before surgery, no diarrhea, markedly less adhesion formation and intestinal passage obstruction. Thus, BPC 157 regimens resolve the duodenal/colon lesions and duodenocolic fistulas in rats, and rapid vessels recovery appears as the essential point in the implementation of the cytoprotection concept in the fistula therapy.

Limitations: Animal study only — human translation uncertain.

Co-extraction and analysis of several different peptides such as insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine insulin and porcine insulin), growth hormone releasing hormones (sermorelin, CJC-1295 and tesamorelin), insulin-like growth factors (long-R3-IGF-I, R3-IGF-I and Des1-3-IGF-I) and mechano growth factors (human MGF and MGF-Goldspink) with criteria that fulfil the requirements of the WADA documents (TD2022 MRPL) for doping controls. The proof of principle was shown by the analysis of post administration samples after treatment with synthetic insulin analogues.

Limitations: Animal study only — human translation uncertain.

Exposure to 3-NP decreased the amount of weight rats gained, impaired spatial learning and memory consolidation, and led to marked motor dysfunction. From our observations and analysis, PNB-0408 did not protect rats from the deficits induced by 3-NP neurotoxicity.

Limitations: Animal study only — human translation uncertain.

In this study, we observed that FOXO4-DRI, a specific FOXO4- p53 binding blocker, induced apoptosis in senescent Leydig cells, reduced the secretion of certain Senescence-Associated Secretory Phenotype and improved the proliferation of cocultured GC-1 SPG cells. In naturally aged mice, FOXO4-DRI-treated aged mice exhibited increased sperm quality and improved spermatogenesis.

Limitations: Animal study only — human translation uncertain.

In addition, preliminary observations suggest GHK can partially reverse cognitive impairment in aging mice by targeting anti-inflammatory and epigenetic pathways. The evidence as presented provides the rationale to further investigate this naturally occurring peptide in preclinical and clinical aging studies.

Limitations: Animal study only — human translation uncertain. Preliminary/pilot study — needs larger trials.

Thus, our results suggest that GHK-Cu acts as a potential drug by attenuating alveolar macrophage oxidative stress. This, in turn, attenuates the progression of pulmonary inflammation and fibrosis, which provides a reference for the treatment of silicosis.

Limitations: No placebo control reported.

Finally, we investigated the effects of copper on enhancing paraquat toxicity and report a protective effect of GHK. We therefore conclude that GHK has potential as a cytoprotective compound with regard to copper and zinc toxicity, with positive effects on protein solubility and aggregation that warrant further investigation in the treatment of neurodegenerative diseases.

Limitations: No placebo control reported.

Hepatic and muscular gene expression of IGFBPs one to three was similar between oIGF-1 and SAL. We conclude that oIGF-1 promotes tissue and organ-specific growth in the normal sheep fetus.

Limitations: In-vitro study — may not reflect in-vivo effects.

Furthermore, the concentrations of luteinizing hormone (LH) and 11-ketotestosterone (11-KT) in the serum of fish treated with either 5 or 30&#x202f;&#xb5;g of IPA were significantly elevated in comparison to the control group. Collectively, these findings suggest that the administration of ghrelin enhances the development of germ cells during the meiosis-I phase and that this effect might be mediated via the stimulation of 11-KT and androgen receptors at the testicular level and LH at the pituitary level in the tilapia.

Limitations: Animal study only — human translation uncertain.

had beneficial effects in alleviating cisplatin-induced weight loss during delayed phase, and these effects were seen when centrally administered anamorelin. Anamorelin inhibited cisplatin-induced acute emesis following intracerebroventricular but not intraperitoneal administration, suggesting that brain penetration is important for its anti-emetic mechanism of action.

Limitations: Animal study only — human translation uncertain.

Using the validated confirmation procedure, a black-market vial of kisspeptin-10 was analysed. The product contained no unexpected impurities, although it appeared to have undergone more degradation than the purchased reference standard.

Limitations: No placebo control reported.

Kiss1, Gpr54 and Dusp18 knockout mice all exhibit osteoclast hyperactivation and bone loss, and Kp-10 abrogated bone loss by suppressing osteoclast activity in vivo. Therefore, Kp-10/Gpr54 is a promising therapeutic target to abrogate bone resorption by Dusp18-mediated Src dephosphorylation.

Limitations: Animal study only — human translation uncertain.

LL-37 was expressed in macrophages and myofibroblasts of capsular tissue in 10 (34%) and nine (31%) of the specimens, respectively. In eight cases (27.5%), it was expressed by both macrophages and myofibroblasts of the same specimen.

Limitations: No placebo control reported.

The effect of LL-37 is time-dependent. As a result, LL-37 may provide rapid and affordable therapies for RVFV infection in Egypt, both during outbreaks and as a preventive strategy.

Limitations: No placebo control reported.

Interestingly, synthetic LL-37, at this concentration, reduces viability of human osteoblast-like MG63&#xa0;cells, whereas the THP-1&#xa0;cells are less sensitive as demonstrated by the MTT assay. In summary, we show that vitamin D enhances hCAP18/LL-37 production, and that this effect can be of physiological/pathophysiological relevance for LL-37-induced human osteoblast toxicity.

Limitations: No placebo control reported.

This review provides a comprehensive discussion of research highlighting the beneficial health effects of LL-37/nucleic acid complexes, as well as discussing observed detrimental effects. We will emphasize why it is important to investigate and elucidate structural characteristics, such as condensation patterns of nucleic acids within complexation, and their mechanisms of action, to shed light on the intricate physiological effects of LL-37 and the seemingly contradictory role of LL-37/nucleic acid complexes in the innate immune response.

Limitations: No placebo control reported. Review article — no new primary data.

Oral LL-37 expression is an important factor in oral homeostasis that maintains the physiological microbiota but is also involved in the development of oral dysbiosis, infectious diseases (including viral, bacterial, and fungal infections), autoimmune diseases, and oral carcinomas. This peptide has also been proposed as a marker of inflammation severity and treatment outcome.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

In addition, cathelicidin LL-37 inhibited the cell cycle and accumulated cells in the S phase. Therefore, these results specify the potential of cathelicidin LL-37 for developing a new and effective anti-Candida agent.

Limitations: In-vitro study — may not reflect in-vivo effects.

Judicious use of protecting groups provides for chemoselective stapling using &#x3b1;-MSH, which provides a basis for investigating both chemoselectivity and affinity. Both classes of stapled peptides show nanomolar Ki's, with one showing a sub-nanomolar Ki value.

Limitations: Animal study only — human translation uncertain.

Cessation of these supplements led to full resolution of symptoms including normalization of hypogonadotropic hypogonadism. This case highlights the need for clinicians to consider commercially available performance-enhancing supplements as potential sources of PEDs and exogenous steroid hormones that can have adverse clinical consequences.

Limitations: In-vitro study — may not reflect in-vivo effects. Case study — cannot establish causation.

MOTS-c negatively correlates with HBV DNA expression (R=-0.71), and its AUC (the area under the curve) for distinguishing CHB from healthy controls is 0.9530, and IA (immune reactive) from IC (inactive HBV carrier) is 0.8689. Inhibition of HBV replication (with a 50-70%&#x2009;inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo.

Limitations: No placebo control reported.

More importantly, MOTS-c displays a marked anti-tumor effect on OC growth without systemic toxicity in vivo. In conclusion, this study reveals a crucial role of MOTS-c in OC and provides a possibility for MOTS-c as a therapeutic target for the treatment of this manlignacy.

Limitations: No placebo control reported.

Notably, Nrf2 deficiency abolished the protective function of MOTS-c in mice with RP. In conclusion, MOTS-c alleviates RP by protecting mitochondrial function through an Nrf2-dependent mechanism, indicating that MOTS-c may be a novel potential protective agent against RP.

Limitations: Animal study only — human translation uncertain.

By using a Bcl-2 inhibitor or adeno-associated virus (AAV)-mediated Bcl-2 knockdown, we further confirm that MOTS-c improves NASH-induced mitochondrial dysfunction, inflammation, and fibrosis, which are dependent on Bcl-2 function. Therefore, our findings show that MOTS-c is a potential therapeutic agent to inhibit the progression of NASH.

Limitations: No placebo control reported.

We highlight several ongoing controversies in the field, and discuss the role of the microbiome in modulating the&#xa0;availability of NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), the presence of multiple cellular compartments that have distinct pools of NAD+ and NADH, and non-canonical NAD+ and NADH degradation pathways. We conclude that a substantial investment in understanding the fundamental biology of NAD+, its detection and its metabolites in specific cells and cellular compartments is needed to support current translational efforts to safely boost NAD+ levels in humans.

Limitations: No placebo control reported. Review article — no new primary data.

This has led to the initiation of several clinical trials with NAD+ precursors to treat accelerated aging, age-associated dysfunctions, and diseases including Alzheimer's and Parkinson's. NAD supplementation has great future potential clinically, and these studies will also provide insight into the mechanisms of aging.

Limitations: No placebo control reported. Review article — no new primary data.

These insights suggest the need for personalized NAD&#x2009;+&#x2009;supplementation strategies, calibrated to individual patient needs and treatment timelines. Clinical trial registration jRCT1020210066.

Limitations: No placebo control reported.

The present results provide a compelling mechanistic link, supported by evidence from human studies, between primary cilia and mitochondrial signaling. Importantly, our findings have significant implications for the development of therapeutic approaches targeting ciliopathies.

Limitations: No placebo control reported.

The literature review for this guideline included studies published up to November 2023. More than 1000 peer-reviewed publications were included, covering the following.

Limitations: No placebo control reported.

The CCDDs using a Minimum Core Test (MCT) significantly increased from 45.7% in 2015 to the current 57.1%. Territorial CCDDs using MCT significantly increased from 24.9% in 2015 to 37% in 2022 (p&#x2009;=&#x2009;0.004).

Limitations: No placebo control reported.

Several other continuous and categorical outcomes generated modest apparent benefits, though nearly all of these outcomes were likely derived post-hoc. Across RECONNECT trial data from two prior publications and the current study, bremelanotide's benefits are statistically modest and limited to outcomes for which scant evidence of validity among women with HSDD exists.

Limitations: No placebo control reported. Review article — no new primary data.

Among 16&#x202f;827 patients, 710 had T2D (194 prescribed semaglutide; 516 prescribed non-GLP-1 RA antidiabetic medications; median [IQR] age, 59 [49-68] years; 369 [52%] female) and 979 were overweight or obese (361 prescribed semaglutide; 618 prescribed non-GLP-1 RA weight-loss medications; median [IQR] age, 47 [32-59] years; 708 [72%] female). In the population with T2D, 17 NAION events occurred in patients prescribed semaglutide vs 6 in the non-GLP-1 RA antidiabetes cohort.

Limitations: No placebo control reported.

Six studies with 1,541 overweight or obese adults were included, and significant weight reductions were observed primarily due to fat mass loss. While the lean mass remained stable in some cases, notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others.

Limitations: Review article — no new primary data.

Semaglutide has a predictable pharmacokinetic profile with a long t1/2 that allows for once-weekly subcutaneous administration. The AUC and Cmax of both oral and subcutaneous semaglutide increased with dose.

Limitations: No placebo control reported. Review article — no new primary data.

Doxorubicin-induced cardiotoxicity is an established model to study cardiac function. Cardiac function was studied by transthoracic echocardiography and invasive hemodynamic monitoring.

Limitations: No placebo control reported.

A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA1c (mean difference -21.61 mmol/mol [-1.96%]) followed by tirzepatide 10 mg (-20.19 mmol/mol [-1.84%]), semaglutide 2.0 mg (-17.74 mmol/mol [-1.59%]), tirzepatide 5 mg (-17.60 mmol/mol [-1.60%]), semaglutide 1.0 mg (-15.25 mmol/mol [-1.39%]) and semaglutide 0.5 mg (-12.00 mmol/mol [-1.09%]).

Limitations: Review article — no new primary data.

Semaglutide, as a once weekly subcutaneous injection for weight management, effectively reduces body mass index (BMI) while improving hyperglycemia, elevated alanine aminotransferase levels, hyperlipidemia, and quality of life in youth with obesity. As of this review, only one large randomized clinical trial of semaglutide in youth has been completed, with a follow-up duration of 68&#x200a;weeks.

Limitations: No placebo control reported. Review article — no new primary data.

Semaglutide was associated with significantly reduced risk for first-time AD diagnosis, most strongly compared with insulin (hazard ratio [HR], 0.33 [95%.

Limitations: No placebo control reported.

The model found that ESG was more cost-effective than semaglutide over a 5-year time horizon, with an ICER of -$595&#x202f;532/QALY. Endoscopic sleeve gastroplasty added 0.06 QALYs and reduced total cost by $33&#x202f;583 relative to semaglutide.

Limitations: No placebo control reported. Case study — cannot establish causation.

In addition, semaglutide also improved the integrity of gut barrier and altered gut microbiota, especially Alloprevotella, Alistpes, Ligilactobacillus and Lactobacillus. In summary, our findings validate that semaglutide induces modifications in the composition of the gut microbiota and ameliorates NAFLD, positioning it as a promising therapeutic candidate for addressing hepatic steatosis and associated inflammation.

Limitations: Animal study only — human translation uncertain.

Twenty-one eligible trials of semaglutide, including 34,721 patients, were identified and considered eligible for the analyses. Globally, semaglutide therapy was not associated with an increased risk of acute pancreatitis (OR 0.7; 95% CI 0.5-1.2, I2 0%).

Limitations: Review article — no new primary data.

A total of 23 studies met the inclusion criteria with a combined sample size of 57,911 participants. The meta-analysis revealed that the adverse event associated with semaglutide is gastrointestinal in nature (nausea and vomiting).

Limitations: Review article — no new primary data.

Nearly all requirements of the recent technical documents from the World Anti-Doping Agency (WADA) considering their minimum required performance levels (MRPL) are fulfilled, and the method was validated for its utilisation as initial testing procedure in doping controls. Finally, the approach was applied to authentic post-administration study urine samples (for insulins and gonadorelin) in order to provide proof of principle.

Limitations: No placebo control reported.

Here, we showed that increased oxidized cardiolipin (ox-CL) and significant mitochondrial damage were accompanied by increased ALCAT1 expression in the glomeruli of patients with DKD. Similar results were found in db/db mouse kidneys and in cultured podocytes stimulated with high glucose (HG).

Limitations: No placebo control reported.

Ten patients entered the OLE; 8 reached the week 168 visit. Elamipretide was well tolerated, with injection-site reactions being the most common adverse events.

Limitations: Standard limitations apply. Check original paper for full discussion.

Subjects with mtDNA pathogenic variants or single large-scale mtDNA deletions represented 74% of the MMPOWER-3 population, with 70% in the mtDNA cohort having either single large-scale mtDNA deletions or MT-TL1 pathogenic variants. Most subjects in the nDNA cohort had pathogenic variants in genes required for mtDNA maintenance (mtDNA replisome), the majority of which were in POLG and TWNK.

Limitations: Standard limitations apply. Check original paper for full discussion.

A novel hierarchical action liposome nanosystem (PHP-DPS@INS) was developed in this study. In terms of delivery, PHP-DPS@INS nanoparticles (NPs) overcame the ocular surface transport barrier by adopting the strategy of "ocular surface electrostatic adhesion-lysosomal site-directed escape".

Limitations: No placebo control reported.

These findings suggest that elamipretide may prevent the progressive development of neurodegenerative diseases via enhancing mitochondrial respiration, mitochondrial biogenesis, mitochondrial fusion, and neural pro-survival pathway, as well as inhibiting mitochondrial fission, oxidative stress, neuroinflammation, toxic protein accumulation, and neural apoptosis. Elamipretide or mitochondrially-targeted peptide might be a targeted agent to attenuate neurodegenerative progression.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

The simultaneous analytical method for TB-500 and its metabolites was developed and validated. The study found that Ac-LK was the primary metabolite with the highest concentration in rats at 0-6 h intervals.

Limitations: No placebo control reported.

Moreover, as our initial results imply, it is not the differentiated, yet most likely the local epidermal progenitor cells which are the primary targets of the molecule. Our present results unveil a new, thus far undiscovered field regarding clinical utilization for TB4 in the future.

Limitations: No placebo control reported.

Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. Tesamorelin led to significant declines in visceral fat (median [interquartile range]: -25 [-93, -2] vs.

Limitations: Standard limitations apply. Check original paper for full discussion.

Both exogenously supplied and adenovirus-produced T&#x3b1;1 orchestrate TAM reprogramming and enhance the antitumor efficacy of ADV via CD8+ T&#xa0;cells, showing promising prospects for clinical translation. Our findings provide inspiration for improving oncolytic adenovirus combination therapy and designing oncolytic engineered adenoviruses.

Limitations: No placebo control reported.

Although PDD presents challenges such as hit validation and target deconvolution, significant achievements have been reached in the era of big data. This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings and discuss how its therapeutic utility in the precision medicine era can be accommodated within the PDD framework.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

More high-quality randomised controlled trials are needed to further confirm Thymosin alpha 1 efficacy. Key Words: Thymosin alpha 1, Efficacy, Acute exacerbation of chronic obstructive pulmonary disease, Meta-analysis.

Limitations: No placebo control reported. Review article — no new primary data.

Contrary to the FDA's restriction on T&#x3b1;1 and 21 additional peptides in 2023, our analysis reveals consistent evidence of T&#x3b1;1's safety and efficacy. The peptide has demonstrated significant effectiveness in treating various conditions, including COVID-19, autoimmune disorders, and cancer.

Limitations: No placebo control reported. Review article — no new primary data.

Tirzepatide also results in clinically important improvements in multiple obesity-related complications including sleep apnea, metabolic-dysfunction associated steatohepatitis, heart failure with preserved ejection fraction and diabetes prevention. Ongoing trials will provide further data on tirzepatide's long-term safety, efficacy (including cardiovascular outcomes) and potential cost-effectiveness for managing overweight/obesity and/or T2D.

Limitations: No placebo control reported. Review article — no new primary data.

The most common adverse events were usually short-lived gastrointestinal-related events, which were generally mild to moderate in nature, including nausea, diarrhoea, decreased appetite and vomiting. Tirzepatide is a valuable addition to the treatment options for people with inadequately controlled T2DM.

Limitations: No placebo control reported. Review article — no new primary data.

Of the 6 articles included in the review, one investigated the use of tirzepatide and showed a statistically significant reduction in area under the plasma drug concentration-time curve, maximum concentration, and time to maximum plasma concentration when tirzepatide was concomitantly administered with an oral hormonal contraceptive. The remaining 5 studies involving GLP-1 RAs did not show a statistically or clinically significant difference of impact of the agents on oral hormonal contraceptives.

Limitations: No placebo control reported. Review article — no new primary data.

Body weight, BMI, WC, FM, FBG, LDL-C, TC, TG and HOMA-IR were significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo, T5 and T2.5 groups. WHR significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo group.

Limitations: Standard limitations apply. Check original paper for full discussion.

A total of 12 randomized controlled trials were included, with a total of 11,758 patients. Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI (body mass index) of patients [MD&#x2009;=&#x2009;-1.71, 95% CI (-2.46, -0.95), p&#x2009;&#x2009;0.05).

Limitations: Review article — no new primary data.

There were 14&#x202f;834 patients treated with tirzepatide (mean [SD] age, 55.4 [11.8] years; 8444 [56.9%] female) and 125&#x202f;474 treated with GLP-1 RA (mean [SD] age, 58.1 [13.3] years; 67&#x202f;474 [53.8%] female). After a median (IQR) follow-up of 10.5 (5.2-15.7) months, 95 patients (0.6%) in the tirzepatide group and 166 (1.1%) in the GLP-1 RA group died.

Limitations: No placebo control reported.

Here, we identified that NNMT can promote IL6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression by decreasing the tri-methyl-histone H3 levels on the promoters of IL6 and CSF2 (encoding GM-CSF) and CCAAT/Enhancer Binding Protein, an essential transcription factor for IL6 expression, thus promoting differentiation of macrophages into M2 type tumor-associated macrophages and generation of myeloid-derived suppressor cells from peripheral blood mononuclear cells. Treatment of xenografted tumor models overexpressing NNMT gallbladder carcinoma (GBC) cells with the NNMT inhibitor JBSNF-000088 resulted in compromised tumor development and decreased expression levels of IL6, GM-CSF, tumor-associated macrophage marker CD206, and myeloid-derived suppressor cell marker CD33 but increased expression levels of CD8.

Limitations: No placebo control reported.

Data were collected from 251 CMT patients (136 women) and 57 controls. MFIS total (mean&#x2009;&#xb1;&#x2009;standard deviation 32&#x2009;&#xb1;&#x2009;18.3, median 33), physical (18.9&#x2009;&#xb1;&#x2009;9.7, 20) and psychosocial (2.9&#x2009;&#xb1;&#x2009;2.4, 3) scores in CMT patients were significantly higher than controls.

Limitations: Standard limitations apply. Check original paper for full discussion.

Furthermore, given in other eye disturbances (i.e., retinal ischemia), BPC 157 instantly breaks a noxious chain of events, both at an early stage and an already advanced stage. Thus, we further advocate BPC 157 as a therapeutic agent in ocular disease.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

In particular, progressing thrombosis, both peripherally and centrally, and heart arrhythmias and infarction that would consistently occur were fully counteracted and/or almost annihilated. To conclude, we suggest further BPC 157 therapy applications.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways. (Current medicinal chemistry, 2023)

Limitations: No placebo control reported.

As recovery with BPC 157 therapy commonly and rapidly occurred, reversing the collapsed azygos vein to the rescuing collateral pathway might initiate rapid direct blood delivery and start blood flow reorganization. In conclusion, we suggest BPC 157 therapy to resolve further vascular and embolization injuries.

Limitations: Animal study only — human translation uncertain.

The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

Limitations: Animal study only — human translation uncertain.

For the MAX assessment, the average MoD across subjects was 1.9 &#xb1; 3.0% BW, and 2S was 15.8 &#xb1; 9.3% BW. The results of this study show that this sensor technology can be used to obtain accurate measurements of peak walking forces with a basic calibration and consequently open new opportunities to monitor GRF outside of the laboratory.

Limitations: Animal study only — human translation uncertain.

Patients with pulmonary arterial hypertension compared with controls exhibited high lung p16, p21, and &#x3b3;-H2AX protein levels, with abundant vascular cells costained for p16, &#x3b3;-H2AX, and 53BP1. Hypoxia increased thoracic bioluminescence in p16LUC/+ mice.

Limitations: Animal study only — human translation uncertain.

We also found the FOXO4-DRI resets the distribution of intranuclear p53 and concurrently decreased the total ECM proteins content. After further validation, FOXO4-DRI may well be a promising therapeutic approach to treating pulmonary fibrosis.

Limitations: Animal study only — human translation uncertain.

Compared with healthy control, plasma GHK levels were decreased in patients with COPD (70.27&#xa0;&#xb1;&#xa0;38.87&#xa0;ng/mL vs. 133.0&#xa0;&#xb1;&#xa0;54.54&#xa0;ng/mL, P&#xa0;=&#xa0;0.009).

Limitations: No placebo control reported.

This study provided a useful method for induced production of laccase by applying GHK chelated metal ion as a non-toxic inducer, which reduced the safety risk of laccase broth and provided the potential application of crude laccase in food industry. In addition, GHK can be used as the carrier of different metal ions to enhance the production of other metalloenzymes.

Limitations: Animal study only — human translation uncertain.

Collectively, decreased plasma GHK levels were related to FAO in asthma patients. Through the direct binding and activation of SIRT1, exogenous GHK-Cu administration alleviated airway remodeling in asthmatic mice.

Limitations: No placebo control reported.

&#x2022; Purified IGF-1 and LR3 IGF-1 show bioactivity comparable to the standard IGF-1. &#x2022; High heterologous expression of IGF-1 and LR3 IGF-1 is achieved by fermentation in a bioreactor.

Limitations: No placebo control reported.

Therefore, we speculate that while acute IGF-1 LR3 infusion may directly suppress insulin secretion, the fetal &#x3b2;-cell in vitro retains the ability to recover GSIS. This may have important implications when considering the long-term effects of treatment modalities for fetal growth restriction.

Limitations: Animal study only — human translation uncertain.

Augmentation of collagen deposition by KiSS-10 is dependent on the protein synthesis elevation, inhibition of MMPs activity (increase of TIMPs release) or decrease of MMPs concentration. The profibrotic activity of KiSS-10 is mediated by FAK and is not dependent on TGF-&#x3b2;1.

Limitations: No placebo control reported.

Consistent with these observations, KP-10 treatment further diminished &#x3b1;-syn and ChAT immunoreactivity in neurons overexpressing wild-type and E46K mutant &#x3b1;-syn. Overall, these findings lend additional credence to the previous notion that KP-10's binding zone may harness efficacious moieties of neuroprotective intent.

Limitations: No placebo control reported.

The findings of our study suggest the effects of KISS on basic ovarian functions. We also observed the influence of BTC on these functions and its ability to modify the effects of KISS on these processes.

Limitations: Animal study only — human translation uncertain.

Interestingly, the LL-37&#x2012;induced distribution of tight junction proteins and improvement in the tight junction barrier were inhibited in autophagy-deficient keratinocytes and keratinocytes and skin models treated with autophagy inhibitors, indicating that the LL-37&#x2012;mediated tight junction barrier is associated with autophagy activation. Collectively, these findings suggest that LL-37 is a potential therapeutic target for skin diseases characterized by dysfunctional autophagy and skin barriers.

Limitations: No placebo control reported.

coli load in the liver and spleen (P&#xa0;<&#xa0;0.01) and restored the structure of the liver and kidney. Taken together, LL-37 conferred protection in a EHEC O157:H7-induced mouse model by reducing intestinal inflammation, enhancing intestinal barrier function, and restoring the balance of the intestinal microbiota, which indicates the therapeutic potential of LL-37 against pathogen infection.

Limitations: No placebo control reported.

In terms of its efficacy and safety in vivo, there are still many questions to be answered. Undoubtedly, LL-37 can open up new windows of opportunity to prevent and treat obstinate biofilm-mediated infections.

Limitations: No placebo control reported. Review article — no new primary data.

Animals fed a HF diet and treated with MT-II demonstrated recognition memory, anxiety, and exploratory behavior similar to the control group. This study provides evidence that even a short-term HF diet has an impact on memory and emotions and is the first study to show that MT-II reverses these changes.

Limitations: Animal study only — human translation uncertain.

A follow-up methodology with an extensive wash procedure was carried out for selected hair samples, which unambiguously verified the presence of MK-0677. Wash criteria to differentiate between internal incorporation (via bloodstream) and external deposition (via sweat and sebum) was also assessed and indicated internal incorporation for the samples collected at later time points (&#x2265;52&#x2009;days) and a combination of internal incorporation and external deposition for hair samples collected at the earlier time point (2&#xa0;days).

Limitations: No placebo control reported.

However, treatment with the AMPK pathway inhibitor compound C (CC) abolishes the positive effect of MOTS-c on LPS stress. Collectively, our research suggests that MOTS-c may attenuate myocardial injury in septic cardiomyopathy by activating AMPK and provides a new idea for therapeutic strategies in septic cardiomyopathy.

Limitations: No placebo control reported.

Therefore, this article reviewed the distribution and function of MOTS-c in the tissue, discussed the latest research developments in the regulation of osteoblasts and osteoclasts, and proposed potential molecular mechanisms for the effect of exercise on the regulation of bone metabolism. This review provides a theoretical reference for establishing methods to prevent and treat skeletal metabolic diseases.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

This article aims to summarize and interpret the interesting and updated findings of MOTS-c-associated genes and pathways involved in pathological metabolic processes. Finally, it is expected to develop novel diagnostic markers and treatment approaches with MOTS-c to prevent and treat metabolic disorders in the future.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

This review focuses mainly on recent advances in MOTS-c research with regards to diabetes, including both type 1 and type 2. The emerging understanding of MOTS-c in diabetes may provide insight into the development of new therapies for diabetes and other age or senescence-related diseases.

Limitations: No placebo control reported. Review article — no new primary data.

Throughout this paper, we discussed the discovery and physiological function of mitochondrial-derived polypeptide MOTS-c, and the application of MOTS-c in the treatment of various diseases, such as aging, cardiovascular disease, insulin resistance, and inflammation. To provide additional ideas for future research and development, we tapped into the molecular mechanisms and therapeutic potentials of MOTS-c to improve diseases and combined the technology with synthetic biology in order to offer a new approach to its development and application.

Limitations: No placebo control reported. Review article — no new primary data.

Additionally, HR promoted ferroptosis in MLE-12&#xa0;cells, and MOTS-c inhibited ferroptosis against HR through the PPAR&#x3b3; signaling pathway. These findings highlight the therapeutic potential of MOTS-c for improving postoperative ALI induced by cardiac surgery.

Limitations: No placebo control reported.

Finally, we explore the proposed mechanisms through which niacin may ameliorate neuropathology. While several questions remain, the prospect of niacin as a therapeutic to alleviate neurological impairment is promising.

Limitations: No placebo control reported. Review article — no new primary data.

NAD + level was elevated in activated NK cells. NAD + supplementation not only enhanced cytokine production and cytotoxicity but also improved the proliferation and viability of NK cells.

Limitations: No placebo control reported.

We also find that NR targets a novel pathway of lipid droplets in the cochlea by inducing the expression of CIDEC and PLIN1 proteins that are downstream of PPAR signaling and are key for lipid droplet growth. Taken together, our results demonstrate the therapeutic potential of NR treatment for ARHL and provide novel insights into its mechanism of action.

Limitations: No placebo control reported.

Nicotinamide Adenine Dinucleotide Supplementation in Parkinson's Disease: A Potential Disease-Modifying Agent Targeting Multiple Pathways. (Movement disorders clinical practice, 2023)

Limitations: Animal study only — human translation uncertain.

Elevated DNA damage was associated with defective DNA repair processes, including NAD-dependent parylation, in HBV-specific CD8 cells of chronic HBV patients. NAD depletion was indicated by the overexpression of CD38, the major NAD consumer, and by the significant improvement of DNA repair mechanisms, and mitochondrial and proteostasis functions by NAD supplementation, which could also improve the HBV-specific antiviral CD8 T cell function.

Limitations: No placebo control reported.

Although data from clinical trials demonstrated a significant change in validated questionnaires, the overall clinical benefit appears to be modest. However, these results should be interpreted in the light of the dramatic challenges in conducting well-designed clinical trials for female sexual dysfunction, due to the significant placebo effect of pharmacotherapy, and the frequent use of outcome measures that are likely to be highly susceptible to expectation biases, such as long periods of recall of sexual and emotional response.

Limitations: Review article — no new primary data.

These approvals have also renewed excitement in the development of therapeutics targeting the melanocortin system. Here, we review the anatomy and function of the melanocortin system, discuss progress and challenges in developing melanocortin receptor-based therapeutics, and outline potential metabolic and behavioural disorders that could be addressed using pharmacological agents targeting these receptors.

Limitations: No placebo control reported. Review article — no new primary data.

This Medical News article discusses chronic weight management with semaglutide, sold under the brand names Ozempic and Wegovy.

Limitations: No placebo control reported.

Whether and to which extent the effect is direct is still a matter of debate and an intriguing topic to investigate for suitable preventative and rehabilitative purposes. In this minireview, we will summarize the available data and suggest guidelines for a comprehensive semaglutide clinical utilization until new evidence becomes available.

Limitations: No placebo control reported. Review article — no new primary data.

This shift marks a transformative approach to obesity management and CVD prevention. However, further research is needed to fully comprehend semaglutide's cardiovascular benefits and potential risks.

Limitations: Review article — no new primary data.

Semaglutide increased sIPSC frequency in CeA and ILC neurons from alcohol-naive rats, suggesting enhanced GABA release, but had no overall effect on GABA transmission in alcohol-dependent rats. In conclusion, the GLP-1 analogue semaglutide decreased alcohol intake across different drinking models and species and modulated central GABA neurotransmission, providing support for clinical testing of semaglutide as a potentially novel pharmacotherapy for AUD.

Limitations: Animal study only — human translation uncertain.

In male and female rats, acute and repeated semaglutide administration reduced alcohol intake and prevented relapse-like drinking. Moreover, fluorescently labelled semaglutide was detected in NAc of alcohol-drinking male and female rats.

Limitations: Animal study only — human translation uncertain.

Semaglutide and pregnancy. (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023)

Limitations: No placebo control reported.

In conclusion, semaglutide inhibits I/R injury-induced cardiomyocyte apoptosis by activating the PKG/PKC&#x3b5;/ERK1/2 pathway. The beneficial effect of GLP-1/GLP-1R, involved in the activation of the PKG/PKC&#x3b5;/ERK1/2 pathway, may provide a novel treatment method for myocardial I/R injury.

Limitations: Animal study only — human translation uncertain.

Among the different regions of the brain, semaglutide concentrations were significantly higher in the hypothalamus. The analytical method and pharmacokinetic information may be helpful toward a better understanding of the effect of semaglutide in the brain and further development of GLP-1 analogs for various brain diseases.

Limitations: Animal study only — human translation uncertain.

In participants completing the Control of Eating Questionnaire (semaglutide, n&#xa0;=&#xa0;88; placebo, n&#xa0;=&#xa0;86), mean body weight changes were&#x2009;-14.8% (semaglutide) and&#x2009;-2.4% (placebo). Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p&#x2009;<&#x2009;0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p&#x2009;<&#x2009;0.05); and for hunger and fullness at week 20 (p&#x2009;<&#x2009;0.001).

Limitations: Standard limitations apply. Check original paper for full discussion.

The most common adverse events reported in STEP 1-5 were gastrointestinal events, which were transient, mild-to-moderate in severity, and typically resolved without permanent treatment discontinuation. This article reviews the data from STEP 1-5 and highlights clinically relevant findings for primary care providers.

Limitations: Review article — no new primary data.

GHRP-4, GHRP-6 and Sermorelin (22-29) can be considered as in-house ISs as they were stable to enzyme and blood treatment and can be used for the quantification of peptides in biological samples. Peptides GHRP-6 and Sermorelin (22-29) were used to analyse a dimeric peptide (26 [F] LfcinB (20-30)2 ) in four different matrices to test these peptides as in-house IS.

Limitations: No placebo control reported.

An optimized C18 SPE was used for that purpose in order to provide low sample conductivity (<130&#xa0;&#xb5;S/cm) and preserve the efficiency of LVSS preconcentration. SEF of 640 was obtained with desalted urine spiked with sermorelin by comparison to the CZE (without preconcentration) method.

Limitations: No placebo control reported.

Participants (N = 218) were randomized (n = 109 elamipretide; n = 109 placebo). The m0ean age was 45.6 years (64% women; 94% White).

Limitations: Standard limitations apply. Check original paper for full discussion.

Ultimately, we applied asiatic acid (a p38-MAPK agonist) to test whether SS-31 regulated cPLA2 partially through the MAPK-P38 signalling pathway. Our group is the first to suggest that SS-31 promotes functional recovery partially by inhibiting cPLA2-mediated autophagy impairment and preventing LMP and pyroptosis after SCI, which may have potential clinical application value.

Limitations: Animal study only — human translation uncertain.

These findings indicated that SS-31 protected against pulmonary fibrosis and inflammation by inhibiting the Nrf2-mediated NLRP3 inflammasome in macrophages. Our data provide initial evidence for the therapeutic efficacy of SS-31 in IPF.

Limitations: Animal study only — human translation uncertain.

Endothelial Sirt1 deficiency, by inhibiting autophagy and activating nuclear factor-kappa B signaling, augments expression and secretion of thymosin beta-4 (T&#x3b2;4) that promotes insulin signaling in skeletal myotubes. Thus, unlike in skeletal myocytes, Sirt1 deficiency in the endothelium promotes glucose homeostasis by stimulating skeletal muscle insulin sensitivity through a blood-borne mechanism, and augmented secretion of T&#x3b2;4 by Sirt1-deficient endothelial cells boosts insulin signaling in skeletal muscle cells.

Limitations: Animal study only — human translation uncertain.

Moreover, we discovered TB4 is capable of epicardial progenitor activation, and revealed the effect is independent of hypoxic injury. By observing the above results, we believe, further discoveries and consequential postnatal administration of developmentally relevant candidate molecules such as TB4 may likely result in reversing aging processes and accelerate organ regeneration in the human body.

Limitations: No placebo control reported. Review article — no new primary data.

It prevented LPS-induced amyloid burden in APP/PS1 mice but increased astrocytic and microglial proliferation in the hippocampus of LPS-treated WT mice. These data show that T&#x3b2;4 can alleviate the adverse effects of systemic LPS in the brain by preventing exacerbation of amyloid deposition in AD mice and by inducing reactive microgliosis in aging WT mice.

Limitations: Animal study only — human translation uncertain.

Adjunctive thymosin beta 4 treatment holds novel therapeutic potential to regulate and, optimally, resolve disease pathogenesis in the cornea and perhaps other infectious and immune-based inflammatory disease. We plan to establish the importance of thymosin beta 4 as a therapeutic agent in conjunction with antibiotics with high impact for immediate clinical development.

Limitations: No placebo control reported.

Interestingly, a balance of neurotrophic factors (nerve growth factor and brain-derived neurotrophic factor) and receptors (nerve growth factor receptor p75, tropomyosin related kinase A and B) were competitively maintained by T&#x3b2;4 through receptors reacting to PrP (106-126). Our results demonstrate that T&#x3b2;4 protects neuronal cells against PrP (106-126) neurotoxicity via the interaction of neurotrophic factors/receptors.

Limitations: No placebo control reported.

Herein, we summarize research progression in the field of thymus-mediated immunoendocrine control of cancer, providing insights into how manipulation of the thymic microenvironment can influence treatment outcomes, including clinical responses and adverse effects of therapies. We review data obtained from clinical and preclinical cancer research to evidence the complexity of immunoendocrine interactions underpinning anti-tumor immunity.

Limitations: No placebo control reported. Review article — no new primary data.

A total of 49 patients were included in this analysis. Compared with control patients, the incidence of clinical recovery was higher for treated patients with either baseline low-flow oxygen (subdistribution hazard ratio, 1.48 [95% confidence interval, .68-3.25]) or baseline high-flow oxygen (1.28 [.35-4.63]), although neither difference was significant.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.

For treatment of malignancies, the combination of T&#x3b1;-1 and chemotherapy has a strong synergistic effect by enhancing the anti-tumor immune response. On the basis of the pleiotropic effect of T&#x3b1;-1 on immune cells and the promising results of preclinical studies, T&#x3b1;-1 may be a favorable immunomodulator to enhance the curative effect and decrease immune-related adverse events of immune checkpoint inhibitors to develop novel cancer therapies.

Limitations: No placebo control reported.

In severe sepsis, for example, sepsis-induced immunosuppression is increasingly recognized as the overriding immune dysfunction in these vulnerable patients [4] and there is now agreement that many patients with severe sepsis survive the first critical hours of the syndrome but eventually die later due to patients' immunosuppression which make the system difficulty to fight the primary bacterial infection, decreased resistance to secondary nosocomial infections, and reactivation of viral infections [5]. T&#x3b1;1 has been shown to restore immune functions and help to reduce mortality in patients with severe sepsis.

Limitations: No placebo control reported.

Pooled data from 8 studies indicated that moderate to critical Covid-19 patients who were receiving thymosin alpha-1 therapy had significantly lower mortality from COVID-19 (RR 0.59; 95% CI 0.37-0.93, p&#x2009;=&#x2009;0.02, I2&#x2009;=&#x2009;84%), but without any difference in the needs for mechanical ventilation (RR 0.83; 95% CI 0.48-1.44, p&#x2009;=&#x2009;0.51, I2&#x2009;=&#x2009;74%) and hospital length of stay (MD 2.32; 95% CI -&#xa0;0.93, 5.58, p&#x2009;=&#x2009;0.16, I2&#x2009;=&#x2009;94%) compared to placebo. The benefits of thymosin alpha-1 on the mortality rate were significantly affected only by sample size (p&#x2009;=&#x2009;0.0000) and sex (p&#x2009;=&#x2009;0.0117).

Limitations: Review article — no new primary data.

Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite versus placebo.

Limitations: Standard limitations apply. Check original paper for full discussion.

Evidence from five SURPASS clinical trials has demonstrated that tirzepatide has potent glucose lowering and weight loss with adverse effects comparable to GLP-1 receptor agonists. This paper gives an overview of tirzepatide and SURPASS clinical trials.

Limitations: No placebo control reported.

Among 1428 randomized participants (824 [57.7%] women; mean [SD] age, 58.8 [9.7] years; mean [SD] HbA1c, 8.8% [1.0%]), 1304 (91.3%) completed the trial. At week 52, estimated mean change from baseline in HbA1c with tirzepatide (pooled cohort) was -2.1% vs -1.1% with insulin lispro, resulting in mean HbA1c levels of 6.7% vs 7.7% (estimated treatment difference, -0.98% [95% CI, -1.17% to -0.79%]; P&#x2009;<&#x2009;.001); results met noninferiority criteria and statistical superiority was achieved.

Limitations: No placebo control reported.

In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS program and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Moreover, tirzepatide also decreased eGFR slopes in participants with eGFR >60&#xa0;mL/min/1.73 m2 or with normoalbuminuria. We now review the potential kidney health implications of tirzepatide, addressing its structure and function, relationship to current GLP1 receptor agonists, impact of recent results for the treatment and prevention of kidney disease, and expectations for the future.

Limitations: No placebo control reported. Review article — no new primary data.

Ten trials (6836 participants) were included. Gastrointestinal (GI) AEs were the most commonly reported AEs and were dose dependent 39% (95% CI, 35%-43%), 46% (95% CI, 42%-49%), and 49% (95% CI, 38%-60%) for the 5, 10, and 15&#x2005;mg dose, respectively.

Limitations: No placebo control reported. Review article — no new primary data.

RCTs included in this study revealed that among 5800 patients, 78.22% (95%.

Limitations: Review article — no new primary data.

A total of nine trials with 9871 participants (6828 in the tirzepatide group and 3043 in the control group) that met the pre-specified criteria were included. When compared to all control groups consisting of basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly), and placebo, an increased risk of pancreatitis was not found to be significantly associated with tirzepatide (RR 1.46, [95% CI] 0.59 to 3.61; I2&#xa0;=&#xa0;0.0%, p = 0.436).

Limitations: Review article — no new primary data.

The tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is in progress and is expected to be completed in the fall of 2024. Tirzepatide represents an attractive new option and first-in-class agent for the treatment of T2D in people unable to achieve their glycaemic or weight management goals.

Limitations: Review article — no new primary data.

Despite the increasing evidence indicating NNMT as a viable therapeutic target, the development of cell-active inhibitors against this enzyme is lacking. In this review, we provide an overview of the current status of NNMT inhibitor development, relevant in vitro and in vivo studies, and a discussion of the challenges faced in the development of NNMT inhibitors.

Limitations: No placebo control reported. Review article — no new primary data.

Further, the BPC 157 therapy might be the recovery for the disabled heart functioning, and disabled smooth muscle functioning (various sphincters function recovery). Finally, BPC 157, native and stable in human gastric juice, might be a prototype of anti-ulcer cytoprotective peptide for the muscle therapy with high curing potential (very safe profile (lethal dose not achieved), with suited wide effective range (&#xb5;g-ng regimens) and ways of application).

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

This might be the upgrading of the minor vessel to take over the function of the disabled major vessel, competing with and counteracting the Virchow triad circumstances devastatingly present, making possible the recruitment of collateral blood vessels, compensating vessel occlusion and reestablishing the blood flow or bypassing the occluded or ruptured vessel. As a part of the counteraction of the severe vessel and multiorgan failure syndrome, counteracted were the brain, lung, liver, kidney, gastrointestinal lesions, and in particular, the counteraction of the heart arrhythmias and infarction.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Meantime, several reviews suggest that BPC 157, which does not have a lethal dose, has profound cytoprotective activity, used to be demonstrated in ulcerative colitis and multiple sclerosis trials. Likely, it may bring the theory to practical application, starting with the initial argument, no degradation in human gastric juice for more than 24 h, and thereby, the therapeutic effectiveness (including via a therapeutic per-oral regimen) and pleiotropic beneficial effects.

Limitations: No placebo control reported.

BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT, and attenuated gross (no visible infarcted area) and histological damage, ECG (no ST-T ischemic changes), and echocardiography (preservation of systolic left ventricular function) damage induced by isoprenaline. Its effect was associated with a significant decrease in oxidative stress parameters and likely maintained NO system function, providing that BPC 157 interacted with eNOS and COX2 gene expression in a particular way and counteracted the noxious effect of the NOS-blocker, L-NAME.

Limitations: Animal study only — human translation uncertain.

As leading symptoms, increased intraocular pressure and mydriasis, as well as degeneration of retinal ganglion cells, optic nerve head excavation and reduction in optic nerve thickness, generalized severe irregularity of retinal vessels, faint presentation of choroidal vessels and severe optic nerve disc atrophy were all counteracted. In conclusion, we claim that the reversal of the episcleral veins cauterization glaucoma appeared as a consequence of the BPC 157 therapy of the vessel occlusion-induced perilous syndrome.

Limitations: Animal study only — human translation uncertain.

These were used as reference materials to spike into urine together with commercially available parent peptides and a metabolite of sermorelin (sermorelin(3-29)-NH2 ) to develop a sensitive liquid chromatography-tandem mass spectrometry method for their detection to help prove GHRH administration. Limits of detection of the target peptides were generally 1&#xa0;ng/ml (WADA required performance limit) or less.

Limitations: No placebo control reported.

Stability experiments showed the importance of the proper handling of urine samples to avoid degradation of these peptide hormones, especially for sermorelin and its metabolite which were found to rapidly degrade at temperatures >&#xa0;4&#xa0;&#xb0;C and pH values <&#xa0;7 in accordance with earlier studies. Without the need for specific antibodies, this method may be expanded to cover emerging peptide drugs (&#x2265; ~3&#xa0;kDa), as well as their metabolites in the future to facilitate coverage for this class of prohibited substances.

Limitations: Animal study only — human translation uncertain.

The sensory function in all nerve boundaries (peroneal, tibial, sural) returned to nearly normal by 8 weeks (Grade 2.7 on a scale of Grade 0-3 [0&#xa0;=&#xa0;No function; 3&#xa0;=&#xa0;Normal function]) in all groups combined. The peroneal nerve function recovered quickly with return of function at one week (&#x223c;2.0) while sural nerve function recovered rather slowly at four weeks (&#x223c;1.0).

Limitations: Animal study only — human translation uncertain.

We demonstrated that small-molecule cocktail CIP (including CHIR99021, IDE1, and PD0332991) efficiently induced definitive endoderm (DE) formation via increased endogenous TGF-&#x3b2;/Nodal signaling. Furthermore, we identified that combining Vitamin C, Dihexa, and Forskolin (VDF) could substitute growth factors to induce hepatic specification.

Limitations: No placebo control reported.

Epitalon treatment significantly decreased frequency of spindle defects and abnormal distribution of cortical granules during aging for 12h and 24h, while increased mitochondrial membrane potential and DNA copy number of mitochondria, thus decreasing apoptosis of oocytes by 24h of in vitro aging. Our results suggest that Epitalon can delay the aging process of oocytes in vitro via modulating mitochondrial activity and ROS levels.

Limitations: Animal study only — human translation uncertain.

In addition, in this study, we also uncovered an obvious therapeutic effect of FOXO4-DRI on alleviating radiation-induced pulmonary fibrosis (RIPF) by targeting senescence-like fibroblasts in vivo. In conclusion, by targeting senescence, we offer a strategy that simultaneously decreases radioresistance of NSCLC and the incidence of RIPF.

Limitations: No placebo control reported.

However, the cartilage tissue generated from FOXO4-DRI pretreated PDL9 cells displayed lower expression of senescence-relevant secretory factors than that from the untreated control group. Taken together, FOXO4-DRI is able to remove the senescent cells in PDL9 chondrocytes, but its utility in promoting cartilage formation from the in vitro expanded chondrocytes needs further investigation.

Limitations: In-vitro study — may not reflect in-vivo effects.

The inhibited effect of FOXO4-DRI on myofibroblast lead to a downregulation of extracellular matrix (ECM) receptor interaction pathway in BLM-induced PF. Above all, FOXO4-DRI ameliorates BLM-induced PF in mouse and may be served as a viable therapeutic option for PF.

Limitations: Animal study only — human translation uncertain.

GHK-Cu treatment attenuated the CS-induced emphysematous changes and partially reversed the matrix metalloprotein -9 (MMP-9)/tissue inhibitor of metalloproteinases-1 (TIMP-1) imbalance in the lung tissue. GHK-Cu reduced the inflammation and oxidation by decreasing the expression of inflammatory cytokines (IL-1&#x3b2; and TNF-&#x3b1;) in the bronchoalveolar lavage and the enzymatic activity of MPO and MDA in the lung homogenate while restoring the T-AOC and GSH content.

Limitations: Animal study only — human translation uncertain.

We identified His3 as one site of ternary complex formation (conditional binding constant cKCu(GHK)NImHis3Cu(GHK) = 2900 M-1 at pH 7.4), with the second site (cKCu(GHK)NImHisXCu(GHK) = 1700 M-1) likely being supplied by either His128 or His510. Together with the established role of HSA as a molecular shuttle in the blood, these complexes may aid the transport of the exchangeable Cu2+ pool and the functional form of GHK.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.

The work suggests a novel mechanism for the activation of IGF-1 dependent ERK signaling in CHO cells, wherein IQGAP1 plausibly functions as an IGF-1R-associated scaffold protein. Appropriate glycosylation by the enzymes MGAT1 and MGAT5 is thus essential for processing of cell surface receptor IGF-1R, a potential binding partner in IQGAP1 and ERK signaling, the integral components of the IGF pathway.

Limitations: Animal study only — human translation uncertain.

Understanding the influence of kisspeptin on the reproductive axis and related mechanisms will help the future application of kisspeptin in disease diagnosis and treatment. In this review, we critically appraise the role of kisspeptin in the HPG axis, including its signaling pathways, negative and positive feedback mechanisms, and its control on female and male reproduction.

Limitations: No placebo control reported. Review article — no new primary data.

Supra-vital plasma membrane integrity (%), viable sperm with intact acrosome (%) and DNA integrity (%) were improved (p&#x2009;<&#x2009;0.05) with all doses of kisspeptin-10 as compared to negative control. It was concluded that the addition of 15 and 20&#x2009;&#x3bc;mol&#x2009;L-1 kisspeptin-10 in cryodiluent ameliorated the overall frozen-thawed quality parameters of Nili-Ravi buffalo spermatozoa.

Limitations: Animal study only — human translation uncertain.

Meanwhile, results of dual-luciferase reporter assays indicated that miR-1246 targeted the 3'UTR of StAR in BGCs. These results demonstrated that kp-10 induced P4 synthesis in BGCs by promoting free cholesterol transport via regulating expression of miR-1246/StAR.

Limitations: Animal study only — human translation uncertain.

There were also no KP-10-related findings observed in recovery animals on Day 29. In conclusion, KP-10 demonstrated favorable safety profile in dog where 1,000&#xa0;&#x3bc;g/kg dose was considered as a no-observed-adverse-effect level dose when administered IV once daily for 14&#xa0;days.

Limitations: Animal study only — human translation uncertain.

E2 showed two peaks, at 90&#x2011;120 days and 240&#x2011;270 days. The trends in Kp&#x2011;10 and GnIH concentrations suggest that these two hormones might act to maintain the delicate endocrine equilibrium of pregnancy.

Limitations: Animal study only — human translation uncertain.

Moreover, the total numbers of piglets born and those born alive did not differ among the three groups. These findings suggested that 0.5&#x202f;mg KP-10 given at 96&#x202f;h after weaning could be used in FTAI programmes to manage batch farrowing in sows.

Limitations: Animal study only — human translation uncertain.

Taken together, these observations suggest that LL-37 induces autophagy in endothelial cells but enhances cell death in autophagy-dysfunctional conditions, in which the intracellular degradation of LL-37 is disturbed. Thus, LL-37 may exert an adverse action on autophagy-dysfunctional endothelial cells to induce cell death in the pathogenesis of atherosclerosis.

Limitations: No placebo control reported.

In addition, it has been postulated that LL-37 can directly bind the S1 domain of SARS-CoV-2, mask angiotensin converting enzyme 2 (ACE2) receptors, and limit SARS-CoV-2 infection. Purposeful upregulation of LL-37 could also serve as a preventative and therapeutic strategy for SARS-CoV-2 infections.

Limitations: No placebo control reported. Review article — no new primary data.

Enhanced sampling molecular dynamics simulations were found to be instrumental in outlining how the employed cyclization strategy affects the peptides' conformational behavior and, as a consequence, the detected hMC1R affinity. Additionally, a model of the peptide 5/hMC1R complex employing the very recently reported cryogenic electron microscopy receptor structure was provided.

Limitations: No placebo control reported.

MT-II injected into the NAcc significantly decreased consumption in both home cage and operant paradigms, and furthermore decreased appetitive responding to gain access to food. There was no development of conditioned taste avoidance or change in metabolic parameters following anorexic doses of MT-II.

Limitations: Animal study only — human translation uncertain.

A total of 623 discussion entries were extracted; 205 participants contributed to these entries. Emergent themes included motivation for MT II use, misinformation in the context of using an unregulated product, product preparation and administration, dosing regimens, sunbed use, side effects and concerning practices associated with MT II use.

Limitations: No placebo control reported.

What is the main observation in this case? Co-administration of LGD-4033 and MK-677 increased body mass, lean mass and fat mass, while negatively impacting bone, serum lipids, liver enzymes, testosterone (total and free) and, probably, follicle-stimulating hormone. What insights does it reveal? Our cross-sectional data imply that these compounds might alter intramuscular androgenic hormone and receptor concentrations along with promoting muscular strength, when compared with previously published data from trained males.

Limitations: No placebo control reported. Case study — cannot establish causation.

In this study, 22 metabolites of ibutamoren were identified (17 phase I and 5 phase II). Oxidation of ibutamoren leads to hydroxylated metabolites (mono and di).

Limitations: Animal study only — human translation uncertain.

A total of 32 metabolites for ibutamoren (20 phase I and 12 phase II) were detected. The important findings of the current research are as.

Limitations: Animal study only — human translation uncertain.

In both urine and plasma, the longest duration of detection was observed for an O-dealkylated metabolite of MK-0677, and therefore, this would be the best target for the detection of MK-0677 administration. MK-0677 and the O-dealkylated metabolite were found to be excreted largely unconjugated in urine and plasma.

Limitations: Animal study only — human translation uncertain.

In addition, we found that MOTS-c protects pancreatic &#x3b2;-cell from STZ-mediated injury. Taken together, our findings demonstrate that MOTS-c could be a promising strategy for the treatment of GDM.

Limitations: Animal study only — human translation uncertain.

Exogenous MOTS-c also stimulates thermogenesis in subcutaneous white adipose tissues, thereby enhancing energy expenditure and contributing to the anti-obesity effects of exercise training. This review briefly summarizes the mitohormetic mechanisms of exercise with an emphasis on MOTS-c.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Aging is characterized by gradual loss of (mitochondrial) metabolic balance, decreased muscle homeostasis and eventual diminished physical capability, which potentially can be reversed with MOTS-c treatment. This review examines the latest findings on biological effects of MOTS-c as a nuclear regulatory peptide and focuses on the role of MOTS-c in aging and age-related disorders, including mechanisms of action and therapeutic potential.

Limitations: No placebo control reported. Review article — no new primary data.

Excitingly, both adoptive CAR-T and anti-PD1 immune checkpoint blockade mouse models demonstrate that NAD+ supplementation enhanced the tumor-killing efficacy of T&#xa0;cells. Collectively, this study reveals that an impaired TCR-TUB-NAMPT-NAD+ axis leads to T&#xa0;cell dysfunction in the tumor microenvironment, and an over-the-counter nutrient supplement of NAD+ could boost T-cell-based immunotherapy.

Limitations: No placebo control reported.

Furthermore, we found that the protective effects of CD38 deficiency on VSMC senescence were related to restoration of lysosome dysfunction, particularly with respect to the maintenance of sirtuin-mediated mitochondrial homeostasis and activation of the mitochondria-lysosomal axis in VSMCs. In conclusion, our findings demonstrated that CD38 and its associated intracellular NAD decline are critical for Ang II-induced VSMC senescence and vascular remodeling.

Limitations: No placebo control reported.

This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus. Our results indicate an interplay between NR and host-microbiota in APP/PS1 mice, suggesting that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD.

Limitations: Animal study only — human translation uncertain.

Supplementation with NAD+ precursors or nicotinamide riboside, which enhances or supplements the NAD+metabolome, might have a protective effect on the heart. NAD+ can alleviate chronic heart failure via mitochondrial oxidation-reduction (redox) state mechanism.

Limitations: No placebo control reported.

In addition, Mini-Spadin promotes beta-cell proliferation, suggesting its possible regenerative effect. This study highlights new possible roles of PE in pancreatic beta-cell survival and its derivatives as pharmacological tools against diabetes.

Limitations: Animal study only — human translation uncertain.

Because bremelanotide is a cyclic peptide molecule with a molecular weight of 1025, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, bremelanotide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Limitations: No placebo control reported. Review article — no new primary data.

Studies showed improvements in desire, arousal, and orgasm scores when 1.75 mg of bremelanotide was administered before sexual activity compared to a placebo. Bremelanotide is a promising way to treat HSDD.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Animal studies suggest that bremelanotide may affect female sexual desire by activating presynaptic MC4Rs on neurons in the mPOA of the hypothalamus, leading to increased release of DA, an excitatory neurotransmitter that increases sexual desire. This review presents what is known about the mechanism of action of bremelanotide in the context of treating HSDD.

Limitations: No placebo control reported. Review article — no new primary data.

The clinical development program comprised 3500 subjects in 43 completed studies. In the phase 3 studies, subjects took bremelanotide for up to 18 months.

Limitations: Standard limitations apply. Check original paper for full discussion.

Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; updates on efficacy and safety of vaginal estrogen for genitourinary syndrome of menopause and bremelanotide for HSDD; removal of flibanserin alcohol REMS; and development of new technology to enhance bioavailability and brain delivery of treatments. The DSM-5 revision combining HSDD and FSAD into one diagnostic category is a less accurate characterization of these separate disorders and may hinder access to demonstrated effective treatments for the women with these conditions.

Limitations: No placebo control reported. Review article — no new primary data.

The last decade has seen an increase in the number and type of pharmacologic treatment options for dysfunction primarily associated with menopause and hypoactive sexual desire disorder. Recent publications and systematic reviews have strengthened the safety data of existing FDA-approved medications as well as off-label therapies.

Limitations: No placebo control reported. Review article — no new primary data.

In Study A, 27 of 30 bremelanotide subjects (90.0%) completed the trial and exhibited a significantly greater reduction in body weight after 16&#x2009;days versus placebo [least squares mean difference (95% CI), -1.3 (-1.9 to -0.8) kg; p&#x2009;<&#x2009;.0001]. Mean caloric intake in bremelanotide subjects was decreased versus placebo, with a magnitude of reduction of approximately 400&#x2009;kcal/day throughout Study A (p&#x2009;<&#x2009;.01).

Limitations: Standard limitations apply. Check original paper for full discussion.

Among 1202 patients included in the integrated and subgroup analyses, bremelanotide achieved statistically significant improvements in measures of increased desire and decreased distress associated with low desire across all age, weight, and BMI subgroups, and all baseline bioavailable testosterone quartiles, with few exceptions. Bremelanotide was further associated with statistically significant increases in reported sexual desire (p&#x2009;<&#x2009;0.05) in patients not taking hormonal contraceptives, and with a numerical advantage in those taking hormonal contraceptives.

Limitations: Standard limitations apply. Check original paper for full discussion.

Single intraperitoneal injection of Selank in an anxiolytic dose of 0.3 mg/kg reduced the total index of morphine withdrawal syndrome by 39.6%, significantly (&#x440;<0.0001) attenuated convulsive reactions, ptosis, and posture disorders, and 9-fold increased the tactile sensitivity threshold in morphine-dependent rats in comparison with the group of active control; at the same time, Selank was slightly inferior to diazepam in a dose of 2 mg/kg by pharmacological activity (the decrease in total index of morphine withdrawal syndrome by 49.3% and 13-fold increase in sensitivity threshold). Thus, Selank, like diazepam, weakens the aversive signs of morphine withdrawal in rats with opiate dependence.

Limitations: Animal study only — human translation uncertain.

As a result of the work performed to determine the concentration of pro-inflammatory and anti- inflammatory cytokines, it was found that in the serum of animals exposed to stress, there was a statistically significant increase in the level of IL-1&#x3b2;, IL-6 and TGF-&#x3b2;1 in individuals with both types of behavior. It should be noted that, under the conditions of this stressful impact, there was a tendency to decrease the concentration of IL-4 and increase the level of TNF-&#x3b1; but these indicators were not statistically significant.

Limitations: Animal study only — human translation uncertain.

Due to its potent glucose-lowering effect, patients at risk for deterioration of existing DRP should be carefully monitored if treated with semaglutide, particularly if also treated with insulin. Given the beneficial metabolic and cardiovascular actions of semaglutide, and the low risk for severe adverse events, semaglutide has an overall favorable risk/benefit profile for patient with type 2 diabetes.

Limitations: No placebo control reported. Review article — no new primary data.

Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss.

Limitations: Review article — no new primary data.

The study included 4 randomized controlled trials having a total of 3,613 individuals with obesity without diabetes. The mean difference for weight reduction was -11.85%, favoring semaglutide [95% confidence interval (CI) (-12.81,-10.90), p<0.00001].

Limitations: Review article — no new primary data.

Between Jan 21, 2019 and June 4, 2019, 437 participants were screened, of whom 401 were randomly assigned to semaglutide 2&#xb7;4 mg (n=199), semaglutide 1&#xb7;7 mg (n=101), or placebo (n=101) and included in the intention-to-treat analysis. Estimated mean change in bodyweight from baseline to week 68 was -13&#xb7;2% (SEM 0&#xb7;5) in the semaglutide 2&#xb7;4 mg group and -9&#xb7;6% (0&#xb7;8) in the semaglutide 1&#xb7;7 mg group versus -2&#xb7;1% (0&#xb7;8) in the placebo group (estimated treatment difference [ETD] -11&#xb7;1 percentage points [95% CI -12&#xb7;9 to -9&#xb7;2] for semaglutide 2&#xb7;4 mg vs placebo; -7&#xb7;5 percentage points [95% CI -9&#xb7;6 to -5&#xb7;4] for semaglutide 1&#xb7;7 mg vs placebo; both p<0&#xb7;0001).

Limitations: Standard limitations apply. Check original paper for full discussion.

The mice body weight, liver weight, blood glucose, TG, TCHO, LDL and pro-inflammatory factors were significantly reduced after semaglutide. Meanwhile, semaglutide increased the SOD level.

Limitations: Animal study only — human translation uncertain.

Semaglutide offers the benefits of a highly effective GLP-1RA in both injectable and oral formulations. Selection of the most appropriate formulation can be made on an individual basis to best suit the patient's preferences and needs.

Limitations: No placebo control reported. Review article — no new primary data.

GI AEs were more common with semaglutide 2.4&#xa0;mg than placebo, with most frequently nausea (43.9% vs. 16.1% of participants), diarrhoea (29.7% vs.

Limitations: Standard limitations apply. Check original paper for full discussion.

After Semaglutide treatment, the food intake and body weight of mice were evidently decreased, while the relative gastrocnemius weight ratio were conversely increased. Meanwhile, the levels of TG, CHO, LDL, HDL, TNF-&#x3b1;, IL-6, IL-1&#x3b2; and HOMA-IR were all observed to decrease remarkably after Semaglutide intervention.

Limitations: Animal study only — human translation uncertain.

A total of 23 randomized trials involving 22,096 patients with T2DM were included. There were 730 incident DR cases-463 in the semaglutide group and 267 in the control group.

Limitations: Review article — no new primary data.

Furthermore, gene enrichment analysis was carried out, and a regulatory gene network was constructed. Thus, the spectra of the common and unique effects of the PGP, PGPL, and Semax peptides under ischemia-reperfusion were distinguished.

Limitations: Animal study only — human translation uncertain.

After high-throughput drug screening, we found that recurrent glioma patients were most sensitive to sermorelin. Further analysis revealed that sermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status.

Limitations: No placebo control reported.

In a rat MI model, the resulting liposomal composite hydrogel improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis. This study reports for the first time a liposomal composite hydrogel that can directly target mitochondria of damaged CMs for a feedback-regulated release of encapsulated liposomes to consume the overproduced pathological ROS for improved CM activity and enhanced MI treatment.

Limitations: Animal study only — human translation uncertain.

In early-phase clinical trials, elamipretide administration has not resulted in any severe adverse events, and it has shown promising improvements in cardiac hemodynamics at highest doses. Nonetheless, additional studies are necessary to describe the long-term safety and efficacy of elamipretide.

Limitations: No placebo control reported. Review article — no new primary data.

Parallel reaction monitoring of a subset of phosphorylation sites revealed that the unmodified peptide reporting for Myot S231 increased with age, but not its phosphorylated form and that both phosphorylated and unphosphorylated forms of the peptide covering cMyBP-C S307 increased, but that elamipretide treatment did not affect these changes. These results suggest that changes to thiol redox state and phosphorylation status are two ways in which age may affect mouse heart function, which can be restored by treatment with elamipretide.

Limitations: Animal study only — human translation uncertain.

Data with elamipretide across multiple models of disease are especially promising, with results from several studies supporting the use of elamipretide as potential therapy for patients with Barth syndrome, particularly where there is a confirmed diagnosis of cardiomyopathy. This review highlights the challenges and opportunities presented in treating Barth syndrome cardiomyopathy patients with elamipretide and addresses evidence supporting the durability of effect of elamipretide as a therapeutic agent for Barth syndrome, especially its likely durable effects on progression of cardiomyopathy following the cessation of drug treatment and the capability of elamipretide to structurally reverse remodel the failing left ventricle at the global, cellular, and molecular level in a gradual manner through specific targeting of the mitochondrial inner membrane.

Limitations: No placebo control reported. Review article — no new primary data.

Through improved recognition of the lipodystrophy disorders, patients (and their affected family members) can be appropriately screened for cardiometabolic, noncardiometabolic, and syndromic abnormalities and undergo treatment with targeted interventions. Notably, insights gained through the study of this rare and extreme phenotype can inform our knowledge of more common disorders of adipose tissue overload, including generalized obesity.

Limitations: No placebo control reported. Case study — cannot establish causation.

In conclusion, T&#x3b1;-1 improved the curative effect of chemotherapy by reversing M2 polarization of efferocytosis-activated macrophages, suggesting that T&#x3b1;-1 injection immediately after chemotherapy may contribute to highly synergistic antitumor effects in patients with breast cancer. SIGNIFICANCE: Thymosin &#x3b1;-1 improves the curative effect of chemotherapy by reversing efferocytosis-induced M2 polarization of macrophages via activation of a TLR7/SHIP1 axis.

Limitations: No placebo control reported.

Among 475 randomized participants (211 [44%] women; mean [SD] age, 60.6 [9.9] years; mean [SD] HbA1c, 8.31% [0.85%]), 451 (94.9%) completed the trial. Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group.

Limitations: Standard limitations apply. Check original paper for full discussion.

Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP. Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.

Limitations: No placebo control reported. Review article — no new primary data.

Seven trials (6609 participants) were included. A dose-dependent superiority in lowering HbA1c was evident with all three tirzepatide doses vs all comparators, with mean differences ranging from -17.71&#xa0;mmol/mol (-1.62%) to -22.35&#xa0;mmol/mol (-2.06%) vs placebo, -3.22&#xa0;mmol/mol (-0.29%) to -10.06&#xa0;mmol/mol (-0.92%) vs GLP-1 RAs, and -7.66&#xa0;mmol/mol (-0.70%) to -12.02&#xa0;mmol/mol (-1.09%) vs basal insulin regimens.

Limitations: Review article — no new primary data.

From April 1, 2019, to Nov 15, 2019, 502 participants were assessed for eligibility to participate in this substudy, 296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74). Baseline demographics and clinical characteristics were similar across all treatment groups.

Limitations: No placebo control reported.

Tirzepatide is in phase III development for heart failure, obesity and cardiovascular disorders in T2DM, and in phase II development for non-alcoholic steatohepatitis. This article summarizes the milestones in the development of tirzepatide leading to this first approval for T2DM.

Limitations: No placebo control reported. Review article — no new primary data.

Between May 7, 2019, and March 31, 2021, 821 participants were assessed for study eligibility and 636 were randomly assigned to receive at least one dose of tirzepatide 5 mg (n=159), 10 mg (n=158), or 15 mg (n=160), or dulaglutide 0&#xb7;75 mg (n=159). 615 (97%) participants completed the study and 21 (3%) discontinued.

Limitations: No placebo control reported.

Between June 28, 2019, and April 8, 2021, we screened 184 individuals and enrolled 117 participants, all of whom were included in the safety population (45 in the tirzepatide 15 mg group, 44 in the semaglutide 1 mg group, and 28 in the placebo group). Because of discontinuations and exclusions due to missing or unevaluable data, 39 patients in each treatment group and 24 patients in the placebo group comprised the pharmacodynamic analysis set.

Limitations: Standard limitations apply. Check original paper for full discussion.

Tirzepatide Once Weekly for the Treatment of Obesity. (The New England journal of medicine, 2022)

Limitations: No placebo control reported.

Chronic alcohol consumption induces endoplasmic reticulum (ER) stress and upregulates NNMT expression in the liver. ER stress inducers upregulated NNMT expression in both AML12 hepatocytes and mice.

Limitations: Animal study only — human translation uncertain.

NNMT is emerging as a key point of intersection between cellular metabolism and epigenetic gene regulation, and growing evidence supports its central role in several pathologies. The use of molecules that target NNMT represents a current pharmaceutical challenge for the treatment of several metabolic-related disease as well as in cancer.

Limitations: No placebo control reported. Review article — no new primary data.

Future Directions: BPC 157 rapidly increases various genes expression in rat excision skin wound. This would define the healing in the other tissues, that is, gastrointestinal tract, tendon, ligament, muscle, bone, nerve, spinal cord, cornea (maintained transparency), and blood vessels, seen with BPC 157 therapy.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Of the 16 patients, 12 had received only BPC 157 as an intra-articular injection. In this group, 11 of the 12 patients (91.6%) had significant improvement in knee pain, whereas 1 patient (8.3 %) had no improvement.

Limitations: No placebo control reported.

Likewise, in BPC 157 therapy, there is specific support for each of these topics: counteracted encephalopathies; alleviated vascular occlusion disturbances (stroke); counteracted dopamine disturbances (dopamine receptors blockade, receptors super sensitivity development, or receptor activation, over-release, nigrostriatal damage, vesicles depletion), and nitric oxide-system disturbances ("L-NAME non-responsive, L-arginine responsive," and "L-NAME responsive, L-arginine responsive") (schizophrenia therapy); inflammation reduction, nerve recovery in addition to alleviated hemostasis and vessels function after compression (spinal cord injury therapy). Thus, these disturbances may be all resolved within the same agent's beneficial activity, i.e., the stable gastric pentadecapeptide BPC 157.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

This beneficial effect occurs equally when the gastrointestinal anastomoses are impaired with the application of NSAIDs, cysteamine, large bowel resection, as well as concomitant esophageal, gastric, and duodenal lesions and/or ulcerative colitis presentation, short bowel syndrome progression, liver and brain disturbances presentation. Particular aspects of the BPC 157 healing of the fistulas are especially emphasized.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

BPC 157 also has an effect on blood vessels, resulting in vessel recruitment that circumvents vessel occlusion and the development of additional shunting and rapid bypass loops to rapidly reestablish the integrity of blood flow (ischemic/reperfusion colitis, duodenal lesions, cecal perforation, and inferior vena caval occlusion). Lastly, BPC 157 counteracts tumor cachexia, muscle wasting, and increases in pro-inflammatory/procachectic cytokines, such as interleukin-6 and tumor necrosis factor-&#x3b1;, and significantly corrects deranged muscle proliferation and myogenesis through changes in the expression of FoxO3a, p-AKT, p-mTOR, and p-GSK-3&#x3b2; (mitigating cancer cachexia).

Limitations: No placebo control reported. Review article — no new primary data.

Furthermore, gastrointestinal irritants such as physical or mental stress, NSAIDs administration, surfactants destroyer such as bile acids, alcohol can lead to leaky gut syndrome through increasing epithelial permeability. In this review article, we described the potential rescuing actions of BPC 157 against leaky gut syndrome after NSAIDs administration for the first time.

Limitations: No placebo control reported. Review article — no new primary data.

In FLT3/ITD AML patients treated with FLT3 inhibitor quizartinib, serum FST levels correlated with clinical response. These observations supported FST as a novel therapeutic target and biomarker in FLT3/ITD AML.

Limitations: No placebo control reported.

Detection of black market follistatin 344. (Drug testing and analysis, 2021)

Limitations: Animal study only — human translation uncertain.

All 11 patients were male, and the mean age was 36.8&#x2009;&#xb1;&#x2009;8.1&#xa0;years. All patients had a history of injecting complete 1&#xa0;mg vials of follistatin-344 subcutaneously in the abdomen.

Limitations: No placebo control reported.

In naturally aged mice, FOXO4-DRI improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency. These findings reveal the therapeutic potential of FOXO4-DRI for the treatment of male late-onset hypogonadism.

Limitations: Animal study only — human translation uncertain.

We conclude that IGF-1-stimulated fetal myocardial growth is accompanied by appropriate expansion and function of the coronary vasculature. These findings support IGF-1 as a potential strategy to increase cardiac myocyte and coronary vascular endowment at birth.

Limitations: Animal study only — human translation uncertain.

In summary, LR3 IGF-1 infusion for 1 wk into late gestation fetal sheep increased the weight of some fetal organs. However, because umbilical amino acid uptake rates and fetal plasma amino acid concentrations were lower in the LR3 IGF-1 group, we speculate that animals treated with LR3 IGF-1 can efficiently utilize available nutrients to support organ-specific growth in the fetus rather than by stimulating placental blood flow or nutrient transfer to the fetus.NEW & NOTEWORTHY After a 1-wk infusion of LR3 IGF-1, late gestation fetal sheep had lower umbilical uptake rates of amino acids, lower fetal arterial amino acid and insulin concentrations, and lower fetal oxygen content; however, LR-3 IGF-1-treated fetuses were still able to effectively utilize the available nutrients and oxygen to support organ growth and myoblast proliferation.

Limitations: Animal study only — human translation uncertain.

Impaired insulin secretion persists in isolated fetal islets indicating an intrinsic islet defect in insulin release when exposed to IGF-1 LR3 infusion for 1 wk. We speculate this alteration in the insulin/IGF-1 axis contributes to the long-term reduction in &#x3b2;-cell function in neonates born with elevated IGF-1 concentrations following pregnancies complicated by diabetes or other conditions associated with fetal overgrowth.NEW & NOTEWORTHY After a 1-wk infusion of IGF-1 LR3, late gestation fetal sheep had lower plasma insulin and glucose concentrations, reduced fetal glucose-stimulated insulin secretion, and decreased fractional insulin secretion from isolated fetal islets without differences in pancreatic insulin content.

Limitations: Animal study only — human translation uncertain.

Altogether, our results suggest a "carpet" membrane dissolution followed by a detergent-like membrane disruption mechanism upon LL-37 activity. This research gives a novel insight into the understanding of LL-37 influence on multicomponent model membranes and a promising contribution to the development of LL-37-derived therapeutic agents against drug-resistant bacteria.

Limitations: No placebo control reported.

Pretreatment with the FPRL1 antagonist inhibited LL-37-induced phosphorylation of ERK and Akt proteins and attenuated LL-37-induced HDLEC migration and tube-like formation. These data indicated that LL-37 induces lymphangiogenesis in lymphatic endothelial cells via FPRL1, and the activation of the ERK and Akt-dependent signaling pathways.

Limitations: No placebo control reported.

Diseased sites had significantly (P <0.05) higher levels of LL-37 and lower levels of HNP 1-3 than healthy sites in both smokers and non-smokers. Diseased sites of smokers presented significantly lower levels of LL-37 and HNP 1-3 when compared with diseased sites of non-smokers.

Limitations: No placebo control reported.

We present a review of Melanotan II and the possible effects of this drug on the kidneys by including a case of a renal infarction most likely attributed to Melanotan II. In the mechanism of renal injury with Melanotan II, thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma must be considered.

Limitations: No placebo control reported. Review article — no new primary data.

Notable structural variations of the Gi and GHSR coupling are observed in our cryo-EM analysis. Our results provide a framework for understanding GHSR signaling and developing new GHSR agonist drugs.

Limitations: No placebo control reported.

These results suggest that through inhibition of myostatin, MOTS-c could be a potential therapy for insulin resistance-induced skeletal muscle atrophy as well as other muscle wasting phenotypes including sarcopenia.NEW & NOTEWORTHY MOTS-c, a mitochondrial-derived peptide reduces high-fat-diet-induced muscle atrophy signaling by reducing myostatin expression. The CK2-PTEN-mTORC2-AKT-FOXO1 pathways play key roles in MOTS-c action on myostatin expression.

Limitations: No placebo control reported.

NR treatment induced mitophagy and improved cognitive and synaptic functions in APP/PS1 mutant mice. Our findings suggest a role for NAD+ depletion-mediated activation of cGAS-STING in neuroinflammation and cellular senescence in AD.

Limitations: No placebo control reported.

In fact, different approaches to replenish or increase NAD levels have been tested, including enhancement of biosynthesis and inhibition of NAD breakdown. Despite further research is needed, this review provides an overview and update on NAD metabolism, including the therapeutic potential of its regulation, as well as pharmacokinetics, safety, precautions and formulation challenges of NAD supplementation.

Limitations: No placebo control reported. Review article — no new primary data.

Consistently, an aberrant induction of NAMPT and PARP activity, together with AIFM1 nuclear translocation, was observed in lesional skin from psoriasis patients. In conclusion, hyperactivation of PARP1 in response to ROS-induced DNA damage, fueled by NAMPT-derived NAD+, mediates skin inflammation through parthanatos cell death.

Limitations: Animal study only — human translation uncertain.

Moreover, nicotinamide adenine dinucleotide, whose levels are tightly controlled by CD38, is a recognized and potent neuroprotective agent, and NAD supplementation was found to be beneficial against neurodegenerative diseases. The aims of this review are to summarize the physiological role played by CD38 in the brain, present the arguments indicating the involvement of CD38 in neurodegeneration and neuroinflammation, and to discuss these observations in light of CD38 complex biology.

Limitations: No placebo control reported. Review article — no new primary data.

The 2 recently approved medications for HSDD, flibanserin and bremelanotide, are reviewed as well as off-label treatments. Overall, HSDD represents a common yet likely underrecognized disorder that midwives and other health care providers who care for women across the life span are in a unique position to address.

Limitations: No placebo control reported. Review article — no new primary data.

Bremelanotide, with even weaker efficacy, capitalised on the regulatory precedent set by the approval of flibanserin. Reconsideration of regulatory decisions to approve these drugs is in order, as well as a broader examination of how future regulatory decisions can better address conflicts of interest and clinically meaningful benefit.

Limitations: No placebo control reported. Review article — no new primary data.

Bremelanotide's modest benefits on incompletely reported post-hoc measures of questionable validity in combination with participants substantially preferring to take placebo suggest that the drug is generally not useful. Kingsberg et al.'s data reporting and measurement practices were incomplete and lacked transparency.

Limitations: Review article — no new primary data.

Because of the validity of a dilution QC that showed accurate quantification of 10-fold diluted plasma samples (accuracy 99.4 %, precision < 6 %), the assay is suitable for bremelanotide quantification in its effective concentration range up to 100,000&#x2009;pg/mL. The ultra-sensitive assay was applied to the quantification of bremelanotide plasma concentrations after oral administration to beagle dogs, which indicated minimal oral absorption.

Limitations: Animal study only — human translation uncertain.

From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2&#xb7;4 mg (n=404), semaglutide 1&#xb7;0 mg (n=403), or placebo (n=403) and included in the intention-to-treat analysis. Estimated change in mean bodyweight from baseline to week 68 was -9&#xb7;6% (SE 0&#xb7;4) with semaglutide 2&#xb7;4 mg vs -3&#xb7;4% (0&#xb7;4) with placebo.

Limitations: Standard limitations apply. Check original paper for full discussion.

Transcriptomic analysis of microdissected brain areas from semaglutide-treated rats showed upregulation of prolactin-releasing hormone and tyrosine hydroxylase in the area postrema. We suggest semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.

Limitations: Animal study only — human translation uncertain.

The area under the concentration-time curve (AUC) for paracetamol 0 to 5 hours after a standardized meal (AUC0-5h,para ; primary endpoint) was increased by 8% (P =&#x2009;0.005) with semaglutide 2.4 mg versus placebo at week 20 (non-significant when corrected for week 20 body weight; P =&#x2009;0.12). No effect was seen on AUC0-1h,para , maximum observed paracetamol concentration, or time to maximum observed paracetamol concentration.

Limitations: Standard limitations apply. Check original paper for full discussion.

The model accurately described concentration profiles across trials. Post-dose fasting time, co-ingestion of a large water volume, and body weight were the most important covariates affecting semaglutide exposure.

Limitations: No placebo control reported.

Between June 19 and Nov 28, 2019, of 1515 adults assessed for eligibility, 961 participants (mean age 58&#xb7;0 years [SD 10&#xb7;0]; 398 [41%] women) were included. Participants were randomly assigned to once-weekly semaglutide 2&#xb7;0 mg (n=480 [50%]) or 1&#xb7;0 mg (n=481 [50%]); 462 (96%) patients in the semaglutide 2&#xb7;0 mg group and 471 (98%) in the semaglutide 1&#xb7;0 mg group completed the trial.

Limitations: No placebo control reported.

Semax exerts a favourable effect on behaviour and biogenic amine system of rats exposed to the antidepressant. Thus, peptide Semax can prevent behavioural deficits caused by altered 5-HT levels during development.

Limitations: Animal study only — human translation uncertain.

Between-group alongwith between-condition differences were revealed in FC between the right amygdala and a region in fusiform, inferior and middle temporal as well as parahippocampal gyri in the right hemisphere. Post hoc analysis allowed us to define both general and specific effects of Selank and Semax on FC between the right amygdala and the right temporal cortex for the first time.

Limitations: Standard limitations apply. Check original paper for full discussion.

This review article discusses the potential candidates for AMD therapy and their known mechanisms of cytoprotection in AMD. These target therapeutic candidates include APE/REF-1, MRZ-99030, Ciliary NeuroTrophic Factor (CNTF), RAP1 GTPase, Celecoxib, and SS-31/Elamipretide.

Limitations: No placebo control reported. Review article — no new primary data.

Surprisingly, we did not observe a synergistic effect between the two drugs in the group receiving both etanercept and MTP-131. One possible explanation for the absence of a synergistic effect is that MTP-131 and etanercept may be acting on different portions of the same pathway.

Limitations: No placebo control reported. Review article — no new primary data.

We demonstrated that T&#x3b2;4 protein level elevated in all APP/PS1 mice. Over-expression of T&#x3b2;4 alone alleviated AD-like phenotypes of APP/PS1 mice, showed less brain A&#x3b2; accumulation and more Insulin-degrading enzyme (IDE), reversed phenotypic polarization of microglia and astrocyte to a healthy state, improved neuronal function and cognitive behavior performance, and accidentally displayed antidepressant-like effect.

Limitations: Animal study only — human translation uncertain.

Participants (193 responders, 148 placebo) were 87% male and 83% white. Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P&#x200a;=&#x200a;0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P&#x200a;=&#x200a;0.29).

Limitations: Standard limitations apply. Check original paper for full discussion.

Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. Our findings inform our knowledge of the biology of pulsatile growth hormone action and provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver.

Limitations: Standard limitations apply. Check original paper for full discussion.

CSF1, a regulator of monocyte recruitment and activation, may serve as an innovative therapeutic target for NAFLD in HIV. Clinical Trials Registry Number: NCT02196831.

Limitations: Standard limitations apply. Check original paper for full discussion.

We propose that these peptides may form a link between somatic cells and immune as well as neuroendocrine systems. This model may provide a better understanding of the mechanisms underlying immune homeostasis, leading thereby to the development of new therapeutic regimes utilizing the characteristics of thymic peptides.

Limitations: No placebo control reported. Review article — no new primary data.

All crude outcomes, including non-recovery rate (65/306 vs. 290/1,976, p = 0.003), in-hospital mortality rate (62/306 vs.

Limitations: No placebo control reported.

From June 3, 2019, to Oct 28, 2020, of 705 individuals assessed for eligibility, 478 (mean baseline HbA1c 7&#xb7;9% [63 mmol/mol], age 54&#xb7;1 years [SD 11&#xb7;9], 231 [48%] women, diabetes duration 4&#xb7;7 years, and body-mass index 31&#xb7;9 kg/m2) were randomly assigned to tirzepatide 5 mg (n=121 [25%]), tirzepatide 10 mg (n=121 [25%]), tirzepatide 15 mg (n=121 [25%]), or placebo (n=115 [24%]). 66 (14%) participants discontinued the study drug and 50 (10%) discontinued the study prematurely.

Limitations: Standard limitations apply. Check original paper for full discussion.

Experiments in primary islets reveal &#x3b2;-arrestin1 limits the insulin response to GLP-1, but not GIP or tirzepatide, suggesting that the biased agonism of tirzepatide enhances insulin secretion. Imbalance toward GIP receptor, combined with distinct signaling properties at the GLP-1 receptor, together may account for the promising efficacy of this investigational agent.

Limitations: Animal study only — human translation uncertain.

This information is based on available published literature. It should not take the place of medical care and advice from your healthcare provider.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Homeostatic model assessment (HOMA) 2-B significantly increased with dulaglutide and tirzepatide 5, 10, and 15 mg compared with placebo (P &#x2264; .02). Proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased with tirzepatide 10 and 15 mg compared with placebo and dulaglutide (P &#x2264; .007).

Limitations: Standard limitations apply. Check original paper for full discussion.

Between April 1 and Nov 15, 2019, we assessed 1947 participants for eligibility, 1444 of whom were randomly assigned to treatment. The modified intention-to-treat population was 1437 participants from the tirzepatide 5 mg (n=358), tirzepatide 10 mg (n=360), tirzepatide 15 mg (n=359), and insulin degludec (n=360) groups.

Limitations: No placebo control reported.

These findings are further supported by isothermal titration calorimetry binding assays as well as modeling studies. The most active NNMT inhibitor identified in the present study demonstrated a dose-dependent inhibitory effect on the cell proliferation of the HSC-2 human oral cancer cell line.

Limitations: No placebo control reported.

BPC 157 counteracts electrocardiogram disturbances (increased P wave amplitude, S1Q3T3 QRS pattern and tachycardia). Rapidly presented vascular pathway (portal vein-superior mesenteric vein-inferior mesenteric vein-rectal veins-left ileal vein-inferior caval vein) as the adequate shunting immediately affected disturbed haemodynamics.

Limitations: Animal study only — human translation uncertain.

Here we demonstrate the confirmation of CJC-1295 in equine plasma by LC-MS/MS after immuno-affinity capture and tryptic digestion. Using this method, CJC-1295 was identified down to concentrations as low as 180&#xa0;pg/mL in 1&#xa0;mL of equine plasma.

Limitations: Animal study only — human translation uncertain.

AEDG peptide and histones H1/3, H1/6 binding may be one of the mechanisms which provides an increase of Nestin, GAP43, &#x3b2; Tubulin III, and Doublecortin neuronal differentiation gene transcription. AEDG peptide can epigenetically regulate neuronal differentiation gene expression and protein synthesis in human stem cells.

Limitations: No placebo control reported.

AEDG and KED peptides could be used as supplementary substances in a culture medium to delay the expression of senescence markers in long term stem cell cultivation in order to promote the large-scale in vitro expansion necessarily required for stem cell therapy clinical application. The data obtained confirm the geroprotective effect of AEDG and KED peptide, which was shown early in animal and cells models.

Limitations: Standard limitations apply. Check original paper for full discussion.

&#x41a;&#x440;&#x43e;&#x43c;&#x435; &#x442;&#x43e;&#x433;&#x43e;, &#x443; &#x43b;&#x44e;&#x434;&#x435;&#x439; &#x441;&#x43e; &#x441;&#x43d;&#x438;&#x436;&#x435;&#x43d;&#x43d;&#x43e;&#x439; &#x43c;&#x435;&#x43b;&#x430;&#x442;&#x43e;&#x43d;&#x438;&#x43d;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x443;&#x44e;&#x449;&#x435;&#x439; &#x444;&#x443;&#x43d;&#x43a;&#x446;&#x438;&#x435;&#x439; &#x44d;&#x43f;&#x438;&#x444;&#x438;&#x437;&#x430;, &#x43f;&#x435;&#x43f;&#x442;&#x438;&#x434; AEDG &#x43d;&#x43e;&#x440;&#x43c;&#x430;&#x43b;&#x438;&#x437;&#x443;&#x435;&#x442; &#x43f;&#x43e;&#x432;&#x44b;&#x448;&#x435;&#x43d;&#x43d;&#x443;&#x44e; &#x44d;&#x43a;&#x441;&#x43f;&#x440;&#x435;&#x441;&#x441;&#x438;&#x44e; &#x446;&#x438;&#x440;&#x43a;&#x430;&#x434;&#x43d;&#x44b;&#x445; &#x433;&#x435;&#x43d;&#x43e;&#x432; Clock &#x438; Csnk1e &#x432; &#x43b;&#x435;&#x439;&#x43a;&#x43e;&#x446;&#x438;&#x442;&#x430;&#x445; &#x438; &#x432; 2 &#x440;&#x430;&#x437;&#x430; &#x43f;&#x43e;&#x432;&#x44b;&#x448;&#x430;&#x435;&#x442; &#x441;&#x43d;&#x438;&#x436;&#x435;&#x43d;&#x43d;&#x443;&#x44e; &#x44d;&#x43a;&#x441;&#x43f;&#x440;&#x435;&#x441;&#x441;&#x438;&#x44e; &#x433;&#x435;&#x43d;&#x430; Cry2 &#x432; &#x43b;&#x438;&#x43c;&#x444;&#x43e;&#x446;&#x438;&#x442;&#x430;&#x445; &#x43a;&#x440;&#x43e;&#x432;&#x438;. &#x412; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x435; &#x433;&#x435;&#x440;&#x43e;&#x43f;&#x440;&#x43e;&#x442;&#x435;&#x43a;&#x442;&#x43e;&#x440;&#x43d;&#x43e;&#x433;&#x43e; &#x44d;&#x444;&#x444;&#x435;&#x43a;&#x442;&#x430; &#x43f;&#x435;&#x43f;&#x442;&#x438;&#x434;&#x430; AEDG &#x43b;&#x435;&#x436;&#x438;&#x442; &#x435;&#x433;&#x43e; &#x441;&#x43f;&#x43e;&#x441;&#x43e;&#x431;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x432;&#x43e;&#x441;&#x441;&#x442;&#x430;&#x43d;&#x430;&#x432;&#x43b;&#x438;&#x432;&#x430;&#x442;&#x44c; &#x43c;&#x435;&#x43b;&#x430;&#x442;&#x43e;&#x43d;&#x438;&#x43d;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x443;&#x44e;&#x449;&#x443;&#x44e; &#x444;&#x443;&#x43d;&#x43a;&#x446;&#x438;&#x44e; &#x44d;&#x43f;&#x438;&#x444;&#x438;&#x437;&#x430; &#x447;&#x435;&#x440;&#x435;&#x437; &#x440;&#x435;&#x433;&#x443;&#x43b;&#x44f;&#x446;&#x438;&#x44e; &#x44d;&#x43a;&#x441;&#x43f;&#x440;&#x435;&#x441;&#x441;&#x438;&#x438; &#x447;&#x430;&#x441;&#x43e;&#x432;&#x44b;&#x445; &#x433;&#x435;&#x43d;&#x43e;&#x432; &#x447;&#x435;&#x43b;&#x43e;&#x432;&#x435;&#x43a;&#x430;.

Limitations: No placebo control reported.

For a sample volume of 100 &#x3bc;L, an LOD of 5 ng/mL could be achieved for serum. Due to the presence of His-tags an unambiguous differentiation from endogenous follistatin is possible.

Limitations: No placebo control reported.

Additionally, the GHK effect on the signal of &#xb7;OH was much stronger than those of other well-known antioxidative, endogenous peptides, carnosine and reduced glutathione. These results suggest that GHK can function as an endogenous antioxidant in living organisms, possibly by diminishing &#xb7;OH and ROO&#xb7;.

Limitations: Animal study only — human translation uncertain.

All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specific hypogonadal symptoms including fat gain and muscular atrophy. However, a paucity of data examining the clinical effects of these compounds currently limits our understanding of GHS' role in the treatment of men with hypogonadism, but does open opportunities for future investigation.

Limitations: No placebo control reported. Review article — no new primary data.

Human studies have demonstrated associations between circulating kisspeptin levels and measures of insulin secretion and insulin resistance; and the only published interventional study has confirmed kisspeptin enhances glucose-stimulated insulin secretion in humans. Further studies are required to elucidate the mechanisms underlying the effects of kisspeptin on the pancreatic &#x3b2;-cell and to determine the therapeutic potential of kisspeptin receptor agonist in the treatment of disorders of glucose homeostasis.

Limitations: No placebo control reported. Review article — no new primary data.

This meta-analysis finally included 12 studies. Compared with controls, women with PCOS showed significantly increased circulatory KISS-1 levels (SMD&#x202f;=&#x202f;0.47; P&#x202f;=&#x202f;0.002).

Limitations: No placebo control reported. Review article — no new primary data.

Between others, they demonstrate high clinical potential as antimicrobial, anti-cancer, immunomodulatory and regenerative agents. Due to continuous research, knowledge on pleiotropic character of natural antibacterial peptides and their mimics is growing, and it is justifying to stay that the therapeutic potential of nanosystems containing membrane active compounds has not been exhausted yet.

Limitations: No placebo control reported. Review article — no new primary data.

LL-37 treatment dramatically increased IFN&#x3b2;1 expression in treated cells in a time-dependent manner. Our results establish LL-37 as a relevant and novel potential therapeutic strategy for the treatment of VEEV infections.

Limitations: No placebo control reported.

Based on the clinical distinction, we propose a new subclassification of EMN: (1) widespread eruptive nevi (WEN), with numerous small nevi, triggered by, for example, drugs and internal diseases, and (2) K&#xf6;bner-like eruptive nevi, often with big and few nevi, associated with skin diseases and most often localized at the site of previous skin disease/trauma. The nature of the data precluded assessment of risk of malignant transformation.

Limitations: No placebo control reported. Review article — no new primary data.

It is hypothesized that cellular fitness requires the coevolved mitonuclear genomes to coordinate adaptive responses using gene-encoded factors that cross-regulate the opposite genome. This suggests that cellular gene expression requires the bipartite split genomes to operate as a unified system, rather than the nucleus being the sole master regulator.

Limitations: No placebo control reported. Review article — no new primary data.

Finally, enhanced neurogenesis and synaptogenesis contributed to the beneficial effects of mini-spadin against stroke and PSD. This work reveals the first evidence that the modulation of TREK-1 channels in the early and chronic phases of stroke as well as the stimulation of brain plasticity by mini-spadin could play a key role in its brain protective effects against stroke and its deleterious consequences such as PSD.

Limitations: No placebo control reported.

Shortened spadin analogs present increased inhibition potency for TREK-1, an improved AD activity, and prolonged in vivo bioavailability. Finally, we also discuss about other inhibitors of TREK-1 channels with a proven efficacy in treating depression in the clinic, such as fluoxetine.

Limitations: No placebo control reported. Review article — no new primary data.

Finally, the action duration of PE 22-28 and its analogs was largely improved in comparison with that of spadin, up to 23 h instead of 7 h. Taken together, our results demonstrated that PE 22-28 and its derivatives represent other promising molecules that could be an alternative to spadin in the treatment of depression.

Limitations: Animal study only — human translation uncertain.

Bremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (&#x3b1;-MSH) with high affinity for the melanocortin type 4 receptor (thought to be important for sexual function), giving it the potential to modulate brain pathways involved in sexual response. This article summarizes the milestones in the development of bremelanotide leading to this first regulatory approval.

Limitations: No placebo control reported. Review article — no new primary data.

Bremelanotide is a subcutaneous injection that can be administered as needed approximately 45 minutes prior to sexual activity. Bremelanotide is safe and has limited drug-drug interactions, including no clinically significant interactions with ethanol.

Limitations: No placebo control reported. Review article — no new primary data.

Study 301 began on January 7, 2015, and concluded on July 26, 2016. Study 302 began on January 28, 2015, and concluded on August 4, 2016.

Limitations: Standard limitations apply. Check original paper for full discussion.

At the same time, our results partially confirm the hypothesis that the peptide may affect the interaction of GABA with GABAA receptors. Our data also suggest that Selank may enhance the effect of olanzapine on the expression of the genes studied.

Limitations: Animal study only — human translation uncertain.

Furthermore, the development of an oral formulation for semaglutide may provide individuals with additional benefits in relation to treatment adherence. In addition to T2D, liraglutide is used in the treatment of obesity, while semaglutide is currently under investigation for use in obesity and NASH.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Mice treated with LPS exhibited mitochondrial dysfunction, oxidative stress, an inflammatory response, neural cell apoptosis, and loss of dendritic spines in the hippocampus, leading to impaired hippocampus-related learning and memory performance in the MWM and contextual fear conditioning test. Treatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment during behavioral tests.

Limitations: Animal study only — human translation uncertain.

However, no research has been done to investigate the effects of T&#x3b2;4 on NAFLD. Based on the findings above mentioned, we hypothesize that T&#x3b2;4 may represent an effective treatment for NAFLD.

Limitations: No placebo control reported. Review article — no new primary data.